US20050113796A1 - Water purification pack - Google Patents
Water purification pack Download PDFInfo
- Publication number
- US20050113796A1 US20050113796A1 US10/997,096 US99709604A US2005113796A1 US 20050113796 A1 US20050113796 A1 US 20050113796A1 US 99709604 A US99709604 A US 99709604A US 2005113796 A1 US2005113796 A1 US 2005113796A1
- Authority
- US
- United States
- Prior art keywords
- fluid
- housing
- reagent
- purified
- bed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000746 purification Methods 0.000 title claims abstract description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 90
- 239000012530 fluid Substances 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 46
- 239000012528 membrane Substances 0.000 claims abstract description 33
- 238000001914 filtration Methods 0.000 claims abstract description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 10
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 7
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 7
- 238000011118 depth filtration Methods 0.000 claims abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 176
- 239000002158 endotoxin Substances 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 24
- 238000011109 contamination Methods 0.000 claims description 8
- 230000004907 flux Effects 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000000356 contaminant Substances 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000005416 organic matter Substances 0.000 claims description 5
- 239000008155 medical solution Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000010999 medical injection Methods 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 13
- 239000007924 injection Substances 0.000 abstract description 13
- 238000001471 micro-filtration Methods 0.000 abstract description 8
- 108010072542 endotoxin binding proteins Proteins 0.000 abstract description 3
- 230000003204 osmotic effect Effects 0.000 abstract description 3
- 235000012206 bottled water Nutrition 0.000 abstract description 2
- 239000003651 drinking water Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 55
- 238000007906 compression Methods 0.000 description 44
- 230000006835 compression Effects 0.000 description 44
- 239000003085 diluting agent Substances 0.000 description 43
- 238000011144 upstream manufacturing Methods 0.000 description 30
- 238000000502 dialysis Methods 0.000 description 22
- 239000000385 dialysis solution Substances 0.000 description 20
- 238000003860 storage Methods 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
- 238000004090 dissolution Methods 0.000 description 19
- 239000008121 dextrose Substances 0.000 description 18
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 210000004379 membrane Anatomy 0.000 description 15
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- -1 sterility Chemical compound 0.000 description 9
- 210000003200 peritoneal cavity Anatomy 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 description 7
- 239000004743 Polypropylene Substances 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000002242 deionisation method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000001223 reverse osmosis Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002262 irrigation Effects 0.000 description 4
- 238000003973 irrigation Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000012508 resin bead Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000168096 Glareolidae Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000011054 oxidizable substance test Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- MKWYFZFMAMBPQK-UHFFFAOYSA-J sodium feredetate Chemical compound [Na+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MKWYFZFMAMBPQK-UHFFFAOYSA-J 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0093—Chemical modification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0079—Manufacture of membranes comprising organic and inorganic components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
- A61M1/1666—Apparatus for preparing dialysates by dissolving solids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
- A61M1/1668—Details of containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/002—Forward osmosis or direct osmosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/002—Forward osmosis or direct osmosis
- B01D61/0021—Forward osmosis or direct osmosis comprising multiple forward osmosis steps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/002—Forward osmosis or direct osmosis
- B01D61/0022—Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/18—Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F21/00—Dissolving
- B01F21/20—Dissolving using flow mixing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F21/00—Dissolving
- B01F21/20—Dissolving using flow mixing
- B01F21/22—Dissolving using flow mixing using additional holders in conduits, containers or pools for keeping the solid material in place, e.g. supports or receptacles
- B01F21/221—Dissolving using flow mixing using additional holders in conduits, containers or pools for keeping the solid material in place, e.g. supports or receptacles comprising constructions for blocking or redispersing undissolved solids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/71—Feed mechanisms
- B01F35/717—Feed mechanisms characterised by the means for feeding the components to the mixer
- B01F35/7179—Feed mechanisms characterised by the means for feeding the components to the mixer using sprayers, nozzles or jets
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/44—Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
- C02F1/444—Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis by ultrafiltration or microfiltration
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F9/00—Multistage treatment of water, waste water or sewage
- C02F9/20—Portable or detachable small-scale multistage treatment devices, e.g. point of use or laboratory water purification systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
- B01F2101/2202—Mixing compositions or mixers in the medical or veterinary field
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/28—Treatment of water, waste water, or sewage by sorption
- C02F1/283—Treatment of water, waste water, or sewage by sorption using coal, charred products, or inorganic mixtures containing them
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/42—Treatment of water, waste water, or sewage by ion-exchange
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
- C02F1/685—Devices for dosing the additives
- C02F1/688—Devices in which the water progressively dissolves a solid compound
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/42—Treatment of water, waste water, or sewage by ion-exchange
- C02F2001/422—Treatment of water, waste water, or sewage by ion-exchange using anionic exchangers
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/42—Treatment of water, waste water, or sewage by ion-exchange
- C02F2001/425—Treatment of water, waste water, or sewage by ion-exchange using cation exchangers
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/04—Non-contaminated water, e.g. for industrial water supply for obtaining ultra-pure water
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A20/00—Water conservation; Efficient water supply; Efficient water use
- Y02A20/20—Controlling water pollution; Waste water treatment
- Y02A20/208—Off-grid powered water treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S210/00—Liquid purification or separation
- Y10S210/90—Ultra pure water, e.g. conductivity water
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S210/00—Liquid purification or separation
- Y10S210/902—Materials removed
- Y10S210/908—Organic
Definitions
- the invention generally relates to water purification, and more particularly to devices and methods for purifying water to a quality suitable for medical applications.
- dialysis Treatments for patients having substantially impaired renal function, or kidney failure, are known as “dialysis.” Either blood dialysis (“hemodialysis”) or peritoneal dialysis methods may be employed. Both methods essentially involve the removal of toxins from body fluids by diffusion of the toxins from the body fluids into a toxin free dialysis solution. Peritoneal dialysis can be performed without complex equipment and in a patient's home. In the peritoneal dialysis process, the patient's peritoneal cavity is filled with a dialysate solution.
- Dialysates are formulated with a high concentration of the dextrose, as compared to body fluids, resulting in an osmotic gradient within the peritoneal cavity.
- the effect of this gradient is to cause body fluids, including impurities, to pass through the peritoneal membrane and mix with the dialysate. By flushing the dialysate from the cavity, the impurities can be removed.
- Peritoneal dialysis may be performed intermittently or continuously.
- IPD intermittent peritoneal dialysis
- the patient commonly receives two liters of dialysate at a time.
- CPD continuous ambulatory peritoneal dialysis
- the peritoneal cavity is filled with two liters of dialysate and the patient is the free to move about while diffusion carries toxins into the peritoneal cavity.
- CCPD Continuous Cycle Peritoneal Dialysis
- CCPD Continuous Cycle Peritoneal Dialysis
- peritoneal dialysates are administered directly into the patient's body, it is important that the dialysis solution maintains the correct proportions and concentrations of reagents. Moreover, it is impractical to formulate and mix dialysis solutions on site at the typical location of administration, such as the patient's home. Accordingly, peritoneal dialysates are typically delivered to the site of administration in pre-mixed solutions.
- peritoneal dialysis solutions are typically acidified, such as with hydrochloric acid, lactate or acetate, to a pH between 4.0 and 6.5.
- the ideal pH level for a peritoneal dialysate is between 7.2 and 7.4. While achieving the desired goal of stabilizing dextrose in solution, the pH of acidified peritoneal dialysis solutions tends to damage the body's natural membranes after extended periods of dialysis. Additionally, the use of acidified peritoneal dialysates tends to induce acidosis in the patient.
- Bicarbonates introduce further instability to dialysis solutions.
- the most physiologically compatible buffer for a peritoneal dialysate is bicarbonate.
- Bicarbonate ions react undesirably with other reagents commonly included in dialysate solutions, such as calcium or magnesium in solution, precipitating out of solution as insoluble calcium carbonate or magnesium carbonate. These insolubles can form even when the reactants are in dry form. When occurring in solution, the reactions also alter the pH balance of the solution through the liberation of carbon dioxide (CO 2 ).
- CO 2 carbon dioxide
- such methods and devices should avoid the problems of non-physiologic solutions and incompatibility of dialysate reagents, and also simplify transportation, storage and mixing of such dialysates.
- One aspect of this problem is the need for mechanisms for safely and completely mixing constituents of dialysates in diluent at the point of administration.
- Another aspect of this problem is the need for producing injectable quality water or other diluent at the point of administration.
- On site purification of fluids is also advantageous in a number of other medical applications, including intravenous injection, intramuscular injection, orally administered fluids, wound irrigation, use in instrument cleaning solutions, and general employment by immuno-compromised individuals (e.g., AIDS patients, geriatrics, etc.).
- immuno-compromised individuals e.g., AIDS patients, geriatrics, etc.
- the apparatus should be transportable and convenient for on-site use in remote locations.
- the embodiments described herein provide a portable apparatus and method for purifying fluid to levels suitable for medical applications, including injection into the human body.
- a portable apparatus for producing injectable quality fluid.
- the apparatus includes a housing that defines a fluid flow path from an inlet port to an outlet port.
- a depth filtration stage, an organic filtration component, a deionization resin bed and a permeable membrane are held within the housing along the fluid flow path.
- the permeable membrane has a porosity of less than about 0.5 ⁇ m and is configured to retain endotoxins.
- a water purification pack for producing injectable quality water includes a container.
- the container defines a flow-through path from an inlet to an outlet with an average cross-sectional area of less than about 20 square inches.
- the container houses purification elements within the path, including a permeable membrane having a porosity of no more than about 0.5 ⁇ m.
- the purification elements provides a back-pressure low enough to allow fluid flow greater than about 30 L/min under a feed pressure of between about 5 psi and 10 psi.
- a method for producing injectable quality of water.
- the method includes providing a portable purification pack with a housing surrounding purification elements in series.
- Non-sterile water is provided to an inlet of the housing under a feed pressure of less than about 20 psi.
- the water passes through the purification elements.
- Purified water exits from an outlet of the housing.
- the purified water has an organic content, conductivity, pH level and particulate contamination level suitable for injection into the human body.
- a method for producing fluid for medical applications.
- the method includes providing a portable housing.
- Non-sterile fluid passes through the housing.
- Particulate contamination, organic matter, dissociated ions, microbes and endotoxins from the feed fluid are retained within purification elements in the housing.
- Fluid suitable for medical applications is then output from the housing.
- FIG. 1 is a schematic side perspective view of a system for producing peritoneal dialysate or other medical solutions
- FIG. 2 is a schematic side sectional view of a fluid purification pack, constructed in accordance with one aspect of the present invention
- FIG. 3 is a schematic side sectional view of a reagent cartridge for housing reagents of peritoneal dialysate
- FIG. 4 shows the reagent cartridge of FIG. 3 after partial dissolution of the reagents housed therein;
- FIG. 5 shows the reagent cartridge of FIG. 3 after complete dissolution of the reagents housed therein;
- FIG. 6 is a schematic side sectional view of a reagent cartridge for housing reagents of peritoneal dialysate
- FIG. 7 shows the reagent cartridge of FIG. 6 after complete dissolution of the reagents housed therein;
- FIGS. 8A and 8B illustrate side sectional and plan views, respectively, of a downstream end of the water purification pack of FIG. 2 ;
- FIGS. 9A and 9B illustrate side sectional and plan views, respectively, of an upstream end of the reagent cartridge of FIG. 3 , configured to irreversibly connect with the water purification pack;
- FIG. 10 is a side sectional view of a coupling between the water purification pack and reagent cartridge of FIGS. 8 and 9 .
- FIG. 1 illustrates a system 10 for producing solutions suitable for injection into the human body.
- a diluent or fluid purification pack 12 as described in more detail below, is connected upstream of a reagent cartridge 14 .
- the cartridge 14 is in fluid communication with a solution reservoir 16 via a tube 18 .
- purified diluent is provided from the pack 12 to the reagent cartridge 14 , wherein the dry reagents are dissolved and solution is delivered to the reservoir 16 .
- the solution can be delivered directly to the patient's body.
- the solution comprises peritoneal dialysis solution.
- the cartridge 14 advantageously houses dry or lyophilized formulations of reagents suitable for peritoneal dialysis.
- the solution is formed immediately prior to delivery to the patient's peritoneal cavity, such that the dialysate need not be stored in solution form for extended periods, and little opportunity exists undesirable reactions within the solution prior to delivery.
- the cartridge 14 defines fluid flow paths through the dry reagents, by way of porous elements therebetween, enabling dry storage in confined reagent beds while also enabling dissolution simply by passing diluent through the housing. Two preferred versions of the cartridge 14 are described in more detail with respect to FIGS. 3-7 , below.
- the diluent purification pack 12 of the illustrated embodiment is capable of on-site purification of locally available fluid, such as tap water from a municipal water source.
- the preferred water purification pack is described in more detail with respect to FIG. 2 below.
- the preferred fluid purification pack 12 is capable of purifying water or other liquid diluent to the standards required for injection into a patient, e.g., for peritoneal dialysis applications.
- available water preferably potable water
- the purified water can be delivered, for example, directly to the reagent cartridge 14 ( FIG. 1 ), to a storage or collection container for short-term storage or transportation or direct connection to another delivery device, such as a wound irrigation pump. Accordingly, bulky purified water need not be stored long in advance of its need or transported great distances to the point of administration. Complex machinery for purifying water is also obviated.
- the U.S. Pharmacopoeia provides processes for producing sterile water for injection.
- the preferred water pack 12 also produces water of a quality suitable for injection, preferably equivalent to or surpassing the quality produced by the U.S. Pharmacopoeia processes. Water purified through the pack thus preferably meets or exceeds the U.S. Pharmacopoeia's standards for Sterile Water for Injection, including sterility, pH, ammonia, calcium, carbon dioxide, chloride, sulfate and oxidizable substances tests.
- injectable quality water or other fluid produced by the illustrated water purification pack 12 exhibits the following characteristics: a very low level of total organic carbon, preferably less than about 1 ppm and more preferably less than about 500 ppb; low conductivity, preferably less than about 5.0 ⁇ Siemens (2.5 ppm) and more preferably less than about 2.0 ⁇ Siemens (1 ppm); near neutral pH, preferably between about 4.5 and 7.5, and more preferably between about 5.0 and 7.0; very low particulate concentration, preferably fewer than less than about 12 particles/mL of particles ⁇ 10 ⁇ m, more preferably less than about 6 particles/mL of such particles, and preferably less than about 2 particles/mL of particles ⁇ 25 ⁇ m, more preferably less than about 1 particle/mL of such particles; and low endotoxin levels, preferably less than about 0.25 endotoxin units (EU) per mL (0.025 ng/mL), more preferably less than about 0.125 EU/mL (0.0125 ng/mL) with a
- U.S. Pat. No. 5,725,777 to Taylor discloses a portable apparatus for purifying water to injectable quality.
- the apparatus includes several stages for purification, including multistage depth prefiltering, ultrafiltration fibers, reverse osmosis fibers, ion exchange resin and activated carbon in that order.
- the water or fluid purification pack 12 comprises a housing 20 with an axial inlet 22 and outlet 24 .
- the housing 20 defines a flow path between the inlet 22 and outlet 24 , with multiple purification stages along the flow path.
- the pack 12 is thus designed to purify fluid in the course of traveling, preferably in a linear path, through the housing 20 .
- the housing 20 is preferably formed of a suitable polymer, particularly polycarbonate, which aids in purifying water by binding endotoxins through charge interactions.
- Endotoxins are the organic byproduct of dead microorganisms, particularly the outer cell wall of bacteria.
- endotoxin is occasionally used to refer to any “cell-associated” bacterial toxin, it primarily refers to the lipopolysaccharide complex associated with the outer envelope of Gram-negative bacteria such as E. coli, Salmonella, Shigella, Pseudomonas, Neisseria, Haemophilus , and other leading pathogens. In high enough concentrations, particularly in critical applications such as intravenous injection, this organic matter can be toxic.
- the pack 12 is configured for convenient portability.
- the outside dimensions of the housing 20 preferably include a length of less than or equal to about 6 inches from inlet 22 to outlet 24 , and a width (diameter in the illustrated embodiment) of less than or equal to about 5 inches.
- the illustrated housing 20 designed for safely purifying 2 L of water, has a length of about 3 inches and a diameter of about 2.25 inches.
- the fluid purification pack 12 has a cross-sectional area of less than about 20 sq. inches, more preferably less than about 4 sq. inches. Despite this small cross-section, the illustrated pack 12 can achieve high flux rates under pressures as low as about 5-10 psi.
- the fluid purification pack 12 is also preferably configured to deliver a unit dose of purified fluid.
- the pack 12 thus is preferably designed for one-time use and to be discarded thereafter. As such, the sterility of the pack 12 can be assured, since the pack 12 will not be reused after seals at the inlet 22 and outlet 24 are broken.
- Several of the features described hereinbelow discourage or prevent recharging the water pack 12 for repeated use, as will be understood by the skilled artisan.
- the porosity limit of the illustrated depth filter 26 preferably ranges from about 1 micron ( ⁇ m) to 10 ⁇ m, most preferably about 1 ⁇ m.
- the depth filter 26 is preferably formed of a porous polypropylene mesh in multiple layers, particularly two to four layers.
- the commercially available cellulose-based depth filters can be employed, as will be understood by one of ordinary skill in the art.
- ceramic or other known particle filtration material can be employed.
- the depth filter 26 comprises a series of depth filters (not shown) that successively filter out smaller and smaller particles. In the illustrated embodiment, four successive depth filters are included within the depth filtration stage 26 , having porosities of about 100 ⁇ m, 40 ⁇ m, 10 ⁇ m and 1 ⁇ m in sequence from upstream end to downstream end.
- an organic filtration stage 28 Downstream of the depth filter 26 is an organic filtration stage 28 , which can comprise a bed of granular carbon.
- the organic filtration stage comprises a resin bed treated for retention of organic contaminants.
- the illustrated embodiment incorporates a form of styrene divinylbenzene commercially available from Rohm & Haas of Philadelphia, Pa. under the trade names Ambersorb 563. This component removes certain residual organic contaminants, such as endotoxins, as well as commonly used additives placed in municipally treated waters (e.g., chlorine, trihalomethanes and chloramine).
- the restraint 30 Adjacent to the downstream end of the organic filtration stage 28 is a restraint 30 .
- the restraint 30 is a filter of controlled porosity, preferably also comprising a polypropylene mesh with a porosity of about 1-10 microns, more preferably about 1 micron. This component prevents passage of particulates shed by the organic filtration component 28 , as well as providing a secondary assurance that insoluble particulates do not pass further through the water purification pack.
- a deionization stage Adjacent to the downstream side of the restraint 30 is a deionization stage, preferably comprising a bed 32 of deionization resin beads.
- the resin bed 32 more preferably comprises a mixture of pharmaceutical grade resins with strong anion exchanger (cation-impregnated) and strong cation exchanger (anion-impregnated) chemistries, binding dissociable ions and other charged particles with a very high affinity.
- the resin bed 32 comprises mixed anion- and cation-impregnated resin beads with weakly associated hydrogen or hydroxyl groups, respectively.
- the ion exchange resins of the preferred embodiment comprise styrene divinyl benzene.
- Cation exchangers exchange hydrogens for any dissolved cations in the diluent. Common dissolved cations include sodium (Na + ), calcium (Ca 2+ ) and aluminum (Al 3+ ).
- the anion exchange resins exchange hydroxyl ions for any anions present in an aqueous solution. Common anions include chloride (Cl ⁇ ) and sulfides (S 2 ⁇ ).
- the resin bed 32 additionally retains some endotoxins that escape the upstream filtration components. The skilled artisan will recognize other types of ion-exchange resins that could also be utilized in this stage.
- the preferred mixed resin bed 32 simplifies and provides a more compact pack 12 than more conventional ion exchange columns, wherein anion and cation exchangers are separated. Moreover, the mixed bed 32 arrangement prevents recharging the ion exchange resin by back-flushing, thus discouraging re-use and maintaining sterility of the unit.
- the restraint 34 Downstream of the deionization resin bed 32 are a deionization bed restraint 34 and a terminal filter element 36 , in sequence.
- the restraint 34 preferably comprises the same polypropylene mesh utilized for the illustrated depth filter 26 and carbon bed restraint 30 .
- the resin bed restraint 34 serves to prevent passage of deionization bed fragments or fines, as well as any other particulates that have escaped the upstream filters 26 , 30 .
- the restraint 34 also serves to protect the filter element 36 downstream of the restraint 34 .
- the terminal filter element 36 comprises a permeable membrane, preferably a microfiltration or ultrafiltration membrane, depending upon the application.
- the term “terminal,” as utilized in this context, refers to the filtration element with the lowest porosity, and not the physical location. Typically, however, the terminal filter will be immediately adjacent the outlet, as shown, such that large particulates are filtered out by courser filtration elements upstream of the terminal filter.
- the terminal filter 36 preferably has a porosity of at most about 0.5 ⁇ m, and none preferably less than about 0.22 ⁇ m.
- an ultrafiltration membrane For applications in remote locations where water is untreated or insufficiently treated, an ultrafiltration membrane is most preferable.
- Nominal porosity of between about 10,000 and 30,000 molecular weight cut-off desirably filters out viruses prevalent in such locations, such as hepatitis, rota virus, polio, etc.
- Nominal cut-off for the illustrated embodiment is between about 15,000 and 25,000 MW.
- endotoxins complex lipopolysaccaride
- an ultrafiltration membrane can retain even a single unit of endotoxin (about 15,000 molecular weight).
- the water purification pack 12 need not filter out pathogenic viruses.
- the terminal filter 36 comprises a microfiltration membrane.
- the higher porosity of a microfiltration membrane allows a greater flow rate for a given feed pressure or a lower feed pressure for a given flow rate.
- the microfiltration membrane preferably has a porosity of lower than about 0.5 ⁇ m, and more preferably comprises a 0.22 ⁇ m or finer filter, and most preferably has a porosity of about 0.20 ⁇ m or finer.
- the terminal filter 36 has enhanced endotoxin binding characteristics and is preferably chemically treated to incorporate a quaternary amine exchanger (QAE) to bind endotoxins.
- QAE quaternary amine exchanger
- the terminal filter 36 comprises two successive QAE-treated 0.20 ⁇ m permeable membranes, ensuring adequate endotoxin retention.
- the terminal filter 36 incorporating a microfiltration membrane removes endotoxins as well as microbes and particulate matter of less than 1 ⁇ m from diluent passing therethrough.
- challenge water with endotoxin levels as high as 1,000 ng/mL have been purified through the illustrated pack 12 to below the current detection limit (0.006 ng/mL).
- the purification stages within the water purification pack are thus such that water passing through the pack 12 and exiting the housing outlet 24 is of a purity level safe for injection into the human body (following the addition of appropriate salts for physiologic solutions).
- effluent water conforms to the purity levels set forth above. It will be understood, of course, that while safe enough for injection, the fluid may actually be employed for alternative medical applications, such as wound irrigation, use in instrument cleaning solutions, and general employment by immuno-comprised individuals (e.g., AIDS patients, geriatrics, etc.).
- the water purification pack 12 includes an upstream cap 38 over the housing inlet 22 , and a downstream cap 40 over the housing outlet 24 .
- the sterility of the purification elements housed within the housing 20 is thus maintained until use.
- the inlet 22 and outlet 24 can be provided with threads or Luer-type fittings (see FIGS. 8-10 ) to mate with upstream and downstream elements in the peritoneal dialysate delivery system 10 ( FIG. 1 ).
- the resin bed 32 preferably comprises a mixed bed of anion- and cation-exchangers.
- the mixed bed 32 cannot be recharged by traditional backflushing techniques, since regeneration of the cation-exchanger would result in exhaustion of the anion exchanger and vice versa.
- the water purification pack is preferably configured to irreversibly connect with a downstream collection device.
- the housing outlet 24 is welded or otherwise integrally connected with a collection tube leading to a collection bag or other container.
- the preferred plastic tubing is simultaneously cut and cauterized to seal the tube downstream of the outlet 24 , preventing re-use of the water pack 12 .
- the outlet 24 is irreversibly connectable with the downstream reagent cartridge 14 .
- the water pack outlet 24 and the reagent cartridge inlet 52 thus have interlocking mechanisms that are irreversible without damage to the mechanisms.
- the water pack housing 20 includes a cylindrical collar 42 surrounding the outlet 24 , the collar having outer ratcheting teeth 44 .
- the reagent pack 14 includes a similar cylindrical collar 46 surrounding the inlet 52 , and the collar 46 includes internal ratchet teeth 48 .
- the outer collar 46 of the reagent pack 14 is sized to fit over the outer collar 42 of the water pack 12 .
- the ratcheting teeth 44 , 46 are sloped to slide past each other during clockwise rotation to tighten the inner Luer lock mechanism.
- the teeth 44 , 46 engage one another, however, to prevent counter-clockwise rotation, such that the Luer lock cannot be loosened.
- the locking mechanism must be broken or otherwise damaged to separate the used water pack 12 from the reagent cartridge 14 . Such damage or breakage minimizes the risk of accidentally re-using a spent water pack 12 .
- similar irreversible locking mechanisms can be utilized with other collection or delivery devices downstream of the water purification pack. The skilled artisan will also recognize other suitable irreversible locking mechanisms for discouraging re-use.
- FIGS. 3-5 illustrate a single-bed reagent cartridge 14 for use with the water purification pack.
- the figures illustrate various stages of dissolution, as will be better understood from the methods of operation discussed hereinbelow.
- FIG. 3 shows a fully charged reagent cartridge 14 , in accordance with the first embodiment.
- the cartridge 14 comprises rigid walled housing 50 with an inlet port 52 at an upstream end, and an outlet port 54 at a downstream end.
- a number of porous elements define a fluid flow path between the inlet port 52 and the outlet port 54 .
- the housing 50 is preferably transparent or translucent, advantageously enabling the user to observe the operation of the device and complete dissolution of reagents prior to use of a produced solution, as will be apparent from the discussion of the method of operation, discussed hereinbelow.
- translucent and transparent polymers are polypropylene, polycarbonate and many other well-known materials.
- an inlet frit 56 which serves as a safety filter to contain any reagent which escapes the restraints described below.
- An outlet frit 58 serves a similar function immediately upstream of the outlet 54 .
- the inlet frit 56 and the outlet frit 58 comprise porous elements having a porosity smaller than the smallest particle of the reagents housed within the cartridge 14 .
- the frits 56 , 58 thus serve as filters to ensure that no reagent escapes the cartridge prior to dissolution, as will be described below.
- An exemplary frit is a multilayered polypropylene laminate, having a porosity between about 1 ⁇ m and 100 ⁇ m, more preferably between about 10 ⁇ m to 50 ⁇ m. Further details on the preferred material are given below, with respect to the reagent restraints.
- upstream reagent compression component 60 Downstream of the inlet frit 56 is an upstream reagent compression component 60 .
- downstream reagent compression component 62 upstream of the outlet frit 58 is a downstream reagent compression component 62 .
- the compression components 60 , 62 preferably comprise materials that have sponge-like elasticity and, as a result of compression, exert axial pressure while trying to return to its original, expanded form.
- the compression components 60 , 62 preferably comprise compressible, porous, open cell polymer or foam, desirably more porous than the frits, to avoid generation of back pressure.
- An exemplary material for the compression components is a polyurethane foam.
- the compression components 60 , 62 and surrounding housing 50 are arranged such that the compression components 60 , 62 exert a compressive force on the reagent bed regardless of the size of the reagent bed.
- the compression components 60 and 62 would, if left uncompressed, together occupy a greater volume than that defined by the housing 50 .
- the pressure exerted is between about 50 grams per sq. inch and 2,000 grams per sq. inch, more preferably between about 300 grams per sq. inch and 900 grams per sq. inch.
- a single reagent bed 64 is situated between the compression components 60 , 62 .
- the reagent bed 64 is desirably sandwiched between an upstream reagent restraint 66 and a downstream reagent restraint 68 .
- the upstream reagent restraint 66 is thus positioned between the reagent bed 64 and the upstream compression component 60
- the downstream reagent restraint 68 is positioned between the reagent bed 64 and the downstream compression component 62 .
- the restraints 66 , 68 desirably prevent the passage of reagent particles in their dry formulation.
- the porosity of the restraints is therefore selected to be less than the size of the smallest particles within the reagent bed, depending upon the particular reagent formulations and physical particle size desired. Desirably, the pores are large enough to avoid excessive pressure drop across the restraints.
- the restraint porosity in the range between about 1 ⁇ m and 100 ⁇ m, more preferably between about 10 ⁇ m to 50 ⁇ m.
- An exemplary restraint suitable for the illustrated peritoneal dialysis application, comprises the same material as the frits 56 , 58 , and consists of a non-woven polymer, particularly polypropylene with a porosity of about 20 microns.
- Another exemplary restraint comprises sintered polyethylene with a porosity of about 30 microns.
- the restraints 66 , 68 are sized and shaped to extend completely across the housing 50 , forming an effective seal against reagent particulates escaping around the restraints 66 , 68 .
- the reagent bed 64 comprises a complete formulation of dry or lyophilized reagents required to produce a peritoneal dialysis solution.
- the reagent bed 65 is a mixture of compatible reagents, such as will not exhibit spontaneous chemical reaction from prolonged contact in their dry form. Accordingly, a buffering agent such as an acetate or lactate, and particularly sodium lactate, is employed in place of a bicarbonate. Further reagents include electrolytes, such as sodium chloride, magnesium chloride, potassium chloride and calcium chloride; a sugar, preferably dextrose; and an acid, particularly citric acid.
- the acid component of the reagent bed 65 can be lower than conventional solutions, since storage in dry form alleviates the tendency for dextrose caramelization.
- the illustrated housing 50 holds reagents sufficient to produce 2 liters of a typical peritoneal dialysate solution. Accordingly, the reagent bed 64 holds the following reagents: TABLE I Dry Reagent Constituents Mass Dry Volume Calcium chloride 514 mg Negligible Magnesium chloride 101.6 mg Negligible Sodium lactate 8.96 g 24 mL Sodium chloride 10.76 g 22 mL Dextrose 50 g 70 mL Total 70 g 116 mL
- the dry volume of the above-listed reagents which can produce 2 L of 2.5% dextrose peritoneal dialysate, is thus about 100 mL.
- the housing 50 for such a formulation need only be about 125% to 500% of the dry reagent volume, more preferably about 150% to 200%, depending upon the selected compression components 60 , 62 .
- the illustrated housing 50 is about 2′′ in diameter and about 3′′ in height, thus occupying about 175 mL.
- the cartridge 14 thus represents a much smaller and more stable form of dialysate for storage and transport, compared to 2 L of prepared solution.
- the skilled artisan can readily determine the proportionate weight and volume of dry reagents required in the reagent bed 64 , such as for producing 1 L, 3 L, 6 L, 10 L, etc. Similarly, the skilled artisan can readily determine the proportions of reagents desirable for 1.5% dextrose dialysate, 4% dextrose dialysate, etc.
- An inlet port cover 70 and an outlet port cover 72 cover the housing inlet port 52 and outlet port 54 , respectively.
- the port covers 70 , 72 advantageously seal out moisture and prevent destabilization of the dry reagents housed within during transport and storage.
- the inlet port 52 and outlet port 54 can be configured with threaded or Luer-type connection fittings.
- the inlet port 52 is configured to mate with the outlet 24 of the water purification pack 12 ( FIG. 2 ), while the outlet port 54 is configured to mate with the downstream tube 18 (see FIG. 1 ).
- FIGS. 6 and 7 illustrate a double-bed reagent cartridge 14 ′.
- FIGS. 6 and 7 illustrate the cartridge 14 ′ in fully charged and fully depleted conditions, respectively, as will be better understood from the methods of operation discussed hereinbelow.
- the housing 50 of the double-bed reagent cartridge 14 ′ is preferably similar to that of the first embodiment, such that like reference numerals are used to refer to like parts.
- the housing 50 defines an inlet port 52 and outlet port 54 , and contains porous elements between the inlet port 52 and outlet port 54 , such as to define a fluid flow path through the housing 50 .
- the housing 50 contains an upstream frit 56 , upstream compression component 60 , upstream reagent restraint 66 , downstream reagent restraint 68 , downstream compression component 62 and downstream frit 58 . Each of these elements can be as described with respect to the previous embodiment.
- reagent beds are confined between the upstream restraint 66 and downstream restraint 68 .
- a primary reagent bed 80 and a secondary reagent bed 82 are shown in the illustrated embodiment, separated by at least one restraint.
- the reagent beds 80 and 82 are separated by a first intermediate restraint 84 and second intermediate restraint 86 , as well as an intermediate compression component 88 between the intermediate restraints 84 and 86 .
- the primary reagent bed 80 is confined between upstream restraint 66 and the first intermediate restraint 84
- the secondary reagent bed 84 is similarly confined between the second intermediate restraint 86 and the downstream restraint 68 .
- the intermediate reagent bed restraints 84 , 86 desirably serve to contain the reagents within the beds 80 , 82 in their dry form, while still being porous enough to allow diluent, along with any dissolved reagents, to pass through.
- the intermediate reagent restraints 84 , 86 can have the same structure as the frits 56 , 58 and upstream and downstream reagent restraints 66 , 68 , as described above with respect to the single-bed embodiment.
- the intermediate compression component 88 can have the same structure as the upstream and downstream compression components 60 , 62 .
- Each of the intermediate compression component 88 and the intermediate reagent restraints 84 , 86 are interposed between and separate the primary reagent bed 80 from the second reagent bed 82 . Due to the selected porosity of the elements, particularly the intermediate restraints 84 , 86 , constituents of the two reagent beds 80 , 82 therefore do not interact with one another in their dry states.
- a complete formulation of the dry reagents required to produce a peritoneal dialysis solution may contain reagents that react undesirably when exposed to one other for prolonged periods of time, in either dry or liquid forms, as noted in the Background section.
- bicarbonates are preferred, physiologically compatible buffering agents for peritoneal dialysis, but tend to be very reactive with typical salts in the dialysate formulation, such as calcium chloride or magnesium chloride.
- the reactions form insoluble calcium carbonate or magnesium carbonate, and also liberate CO 2 . Because of the potential reactivity of incompatible reagents, it is preferable to separately store these reagents within the device housing 50 .
- Separate storage is accomplished by separating reagents into compatible groupings, which are then placed in separate compartments within the housing.
- the compartments are represented, in the illustrated embodiment, by the primary reagent bed 80 and the secondary reagent bed 82 .
- the potentially reactive reagents are thereby constrained from movement through the housing, when maintained in their dry form, by reagent bed restraints 66 , 84 , 86 , 68 at the upstream and downstream ends of each of the reagent beds 80 , 82 .
- the reagent bed restraints 66 , 84 , 86 , 68 have fine enough porosity to prevent the passage of reagent particles in their dry form.
- the primary reagent bed 80 is a reagent mixture, preferably comprising: electrolytes, particularly sodium chloride, potassium chloride, calcium chloride and magnesium chloride; a sugar, particularly dextrose.
- the primary reagent bed 80 can also comprise a buffer.
- the secondary reagent bed 82 can contain at least one component that is unstable in the presence of at least one component in the primary reagent bed 80 .
- the secondary reagent bed 82 contains a bicarbonate, such as sodium bicarbonate. Because the bicarbonate is separated from calcium chloride and magnesium chloride, the reagents do not react to form insoluble precipitates.
- the primary reagent bed 80 can contain the bicarbonate if the secondary bed 82 contains calcium chloride and/or magnesium chloride.
- other incompatible reagents for medical solutions can be similarly separated into reagent beds within the same housing.
- three or more reagent beds can be utilized to separate multiple incompatible reagents.
- the illustrated housing 50 holds reagents sufficient to produce 2 liters of a typical peritoneal dialysate solution. Accordingly, the reagent beds 80 , 82 hold the following reagents: TABLE II Mass Dry Volume Primary Reagent Bed Calcium chloride 514 mg Negligible Magnesium chloride 101.6 mg Negligible Sodium chloride 10.76 g 22 mL Dextrose 50 g 70 mL Subtotal 61 92 mL Secondary Reagent Bed Sodium bicarbonate 6.64 g 6.1 mL Total 68 g 98 mL
- the dry volume of the above-listed reagents which can produce 2 L of 2.5% dextrose peritoneal dialysate, is thus about 98 mL.
- the total volume of the cartridge 14 ′ is preferably between about 125% and 500%, and more preferably 150% and 200%, of the dry reagent volume.
- the skilled artisan can readily determine the proportionate weights and volumes of dry reagents required for forming other peritoneal dialysate solutions, such as 1.5% dextrose dialysate, 4% dextrose dialysate, etc.
- the double-bed cartridge utilizes bicarbonate as the buffer, and omits the need for physiologically damaging acid by enabling production of a physiologic solution.
- purified diluent is provided to a reagent cartridge 14 or 14 ′, which is fully charged with an appropriate amount of dry reagent, as set forth above.
- Fluid to be purified e.g., municipal tap water
- the purified diluent is produced on site and need not be produced remotely and transported, significantly reducing the cost of transportation.
- diluent in the form of available water is first provided to water purification pack 12 of FIG. 2 .
- Pressure commonly found in municipal water systems is sufficient to feed the water through the purification pack 12 .
- a hand pump or large syringe can be supplied with a measured volume of water, and water hand-pumped therefrom into the purification pack 12 .
- Feed pressure is preferably less than about 20 psi.
- Fluid flux through the purification pack 12 (with a feed pressure of about 5-10 psi) is preferably at least about 30 mL/min, and more preferably at least about 90 mL/min through the pack 12 .
- the diluent enters the inlet 22 and passes through depth filter 26 , where particulates larger than about 1 micron are filtered out.
- the depth filter 26 retains insoluble particulates and microbes greater than the pore sizes of the successive layers in this component. Depth filtration is extremely effective in removing contaminants such as asbestos fibers and similarly sized particles.
- Filtered diluent continues downward through organic filtration stage 28 , where residual organics such as endotoxins and additives such as chlorine, chloramine and trihalomethanes are adsorbed. Additionally, some inorganic materials are removed in the process. Carbon is effective at adsorbing many types of chemicals, it is especially known for its power in adsorbing organic compounds. Carbon's particular affinity for organics is due to its non-polar nature. Carbon is also somewhat effective in adsorbing metals and other inorganics. The illustrated resin has similar absorption characteristics.
- the partially purified diluent After being additionally purified by the organic filtration stage 28 , the partially purified diluent passes through the restraint 30 and into the ion-exchange resin bed 32 . Dissociated ions and other charged particulates in solution bind to the resins. Some endotoxins that have escaped the upstream components are also retained in the resin bed 32 .
- the terminal filter 36 comprises an ultrafiltration membrane with a nominal cut-off of between about 10,000 and 30,000 molecular weight. Depending upon the density of pores, 5-10 psi feed pressure can produce a flux of between about 35 mL/min and 100 mL/min through such an ultrafiltration membrane.
- the filter 36 comprises at least one and preferably two microfiltration membranes of a very fine porosity (e.g., about 0.22 ⁇ m or finer), each including chemical treatment with a quaternary amine exchanger for binding residual endotoxins.
- the flux rate for a device with the microfiltration membrane can be more that twice that of an ultrafiltration membrane with equivalent pore density.
- the multiple filtration and chemical binding components of the water purification pack 12 thus ensure removal of particulate, ionic and organic contaminants from the diluent as it passes through the pack 12 .
- Endotoxins including organic matter such as cell walls from dead bacteria, can be particularly toxic.
- Highly purified diluent sufficient to comply with or exceed FDA and U.S. Pharmacopoeia water quality standards for “sterile water for injection,” exits the outlet 24 , but without the need for reverse osmosis.
- purified diluent then passes from the water purification pack 12 to a collection/delivery device.
- the downstream device can comprise a simply storage container, such as a plastic bag.
- the storage/delivery device comprises the reagent cartridge 14 .
- the downstream storage/delivery device is irreversibly fixed to the water pack outlet 24 , either integrally or through a locking mechanism.
- FIGS. 3-5 illustrate dissolution of dry reagent 64 as diluent passes through the single-bed reagent cartridge 14 for the peritoneal dialysis. While illustrated cross-sectionally, it will be understood that the preferred transparent or translucent housing 50 enables the user to similarly observe dissolution of the reagent bed 64 as solvent or diluent passes therethrough. Additionally, the user can observe whether insoluble precipitates are present within the reagent bed, prior to employing the cartridge 14 .
- gravitational force is sufficient to draw the water through the cartridge 14 .
- purified diluent enters the cartridge 14 through the inlet port 52 .
- purified diluent is fed directly from the water purification pack 12 .
- “Directly,” as used herein, does not preclude use of intermediate tubing, etc, but rather refers to the fact that water is purified on site immediately prior to solution formation, rather remotely produced and shipped. It will also be understood, however, that the illustrated reagent cartridge will have utility with other sources of sterile diluent.
- the diluent passes through the porous inlet frit 56 and the upstream compression component 60 .
- the compression component 60 is a porous, open-celled foam, which readily allows diluent to pass therethrough.
- the diluent then passes through the upstream reagent restraint 66 to reach the dry reagent bed 64 .
- the frit 56 and restraint 66 facilitate an even distribution of water flow across the sectional area of the housing 50 .
- the dry reagents are eroded, preferably dissolved, and carried by the diluent through the downstream reagent restraint 68 , the downstream compression component 44 and the outlet frit 58 , exiting through outlet 24 .
- the solution passes through the tube 18 into the collection reservoir 16 (see FIG. 1 ) and then into the peritoneal cavity of a patient.
- the volume of the reagent bed 64 is reduced, as can be seen from a comparison of FIG. 4 with FIG. 3 .
- the compression components 60 , 62 apply continuous compressive force on either side of the reagent bed 64 .
- the compressive force packs the reagents close together.
- Such continuous packing prevents expansion of interstitial spaces as the reagent particles are dissolved.
- the interstitial spaces between the reagent particles tend to expand into larger channels within the reagent bed 64 . These channels would serve as diluent flow paths, which would permit a large volume of diluent to flow through the bed 64 with minimal further dissolution.
- compression components 60 , 62 are preferred, thus compressing the reagent bed 64 from two sides, it will be understood that a single compression component can also serve to keep the regent beds 64 compacted. Moreover, though illustrated in an axial arrangement, such that diluent flows through the compression components 60 , 62 , it will be understood that the compression components can exert a radial force in other arrangements.
- the compressive force of the preferred compression components 60 , 62 exerted evenly across the housing 50 , additionally aids in maintaining the planar configuration of the reagent restraints 66 , 68 on either side of the reagent bed 64 , even as the compression components 60 , 62 move the restraints inwardly.
- the restraints 66 , 68 thus continue to form an effective seal against the housing sidewalls, preventing dry reagent particulates from escaping the bed 64 until dissolved.
- Diluent can continue to flow through the housing 50 into the reservoir 16 ( FIG. 1 ) until the appropriate concentration of peritoneal dialysate solution is formed.
- 2 liters of diluent should be mixed with the contents of the reagent bed 64 . Accordingly, 2 liters of diluent are passed through the housing 50 .
- the contents are typically fully dissolved by the time about 1.5 liters has passed through the housing, but diluent can continue to flow until the appropriate final concentration is reached in the reservoir.
- a concentrate can be first formed and independently diluted.
- the illustrated apparatus and method can form peritoneal dialysis solution simply by passing water through the cartridge 50 , without complex or time consuming mixing equipment.
- the solution can thus be formed on-site, immediately prior to delivery to the peritoneal cavity, such that the dialysate need not be shipped or stored in solution form. Accordingly, a low acid level is possible without undue risk of dextrose carmelization.
- a pre-formed dialysis solution formed has a pH between about 4.0 and 6.5, and the exemplary reagent mix of Table I produces a conventional solution with pH of about 5.2.
- Solution produced from the illustrated single-bed cartridge of FIGS. 3-4 can have lower acidity, since dextrose does not sit in solution for extended periods of time. Accordingly the pH level is preferably between about 6.0 and 7.5, more preferably about 7.0.
- the double-bed reagent cartridge 14 ′ operates in similar fashion.
- Purified diluent is fed to the housing inlet 52 , and passes through the inlet frit 56 , the upstream compression component 60 , the upstream restraint 66 , and into the primary reagent bed 80 .
- Dissolution of reagents in the primary bed 80 forms a solution which passes on through the first intermediate restraint 84 , the intermediate compression component 88 and the second intermediate restraint 86 .
- Reagents in the secondary bed 82 then also dissolve into the diluent, and the enriched solution continues on through the downstream reagent restraint 68 , the downstream compression component 62 and the outlet frit 58 .
- a complete solution thus exits the outlet port 54 .
- the regent beds 80 , 82 are continually compressed as the reagents dissolve.
- Use of three compression components 60 , 88 , 62 has been found to improve dissolution by compressing each bed 80 , 82 from two sides.
- two compression components in the positions of the upstream and downstream third components, can adequately serve to keep the reagent beds compressed enough to aid the rate of dissolution, particularly if provided with a high degree of elasticity.
- a single intermediate compression component in the position of the illustrated intermediate compression component 88 , can accomplish this function, while advantageously also separating the incompatible reagent beds.
- the compression component need not be axially aligned with the reagent beds, but could instead surround or be surrounded by the reagent beds, in which case the compression components would preferably be outside the diluent flow path.
- the illustrated embodiments provide stable, dry forms of peritoneal dialysis solutions.
- Storage and transport of the reagent cartridges of the illustrated embodiments represents considerable cost savings over storage and transport of prepared peritoneal dialysate solutions.
- Dry or lyophilized reagents are moreover more stable than solution, and therefore less harmful to the patient.
- the described embodiments not only provide transport and storage, but additionally provide integrated mechanisms to ensure complete dissolution of the dry reagents. Continuous compression of the reagent bed(s) during dissolution, combined with the transparent windows allowing real time viewing of the dissolution, ensure rapid, complete and verifiable dissolution of the reagents.
- the preferred embodiments can be utilized on site, even in the home, without requiring complex mixing and/or analytical tools.
- physiologically compatible bicarbonate can be employed along with calcium and magnesium. Separate storage and solution preparation only immediately prior to administration enables this combination.
- High dextrose solutions as appropriate for peritoneal dialysis, can be employed without acidic buffers, such that physiologically compatible pH levels can be practically obtained, preferably between about 4.0 and 7.5, and more preferably between about 6.0 and 7.5.
- the reagents listed in Table II produce a solution with a pH of about 7.0.
- the illustrated fluid purification pack 12 is also a compact, conveniently transportable device that facilitates on-site production of injectable quality fluid from available fluid.
- the pack 12 rapidly provides on-site, injectable quality water as input water flows linearly from inlet to outlet.
- a permeable terminal filter 36 represents the lowest porosity element in the pack 12 .
- this element facilitates this high flux at low pressures while still retaining extremely fine particles and toxins.
Abstract
Description
- This application is a continuation of co-pending U.S. application Ser. No. 10/339,702, filed Jan. 8, 2003, which is a divisional of U.S. application Ser. No. 09/364,631, filed Jul. 30, 1999, now U.S. Pat. No. 6,719,745, issued Apr. 13, 2004, which is a continuation-in-part of U.S. application Ser. No. 09/277,448 filed Mar. 26, 1999, now U.S. Pat. No. 6,274,103, issued Aug. 14, 2001.
- The invention generally relates to water purification, and more particularly to devices and methods for purifying water to a quality suitable for medical applications.
- Various medical conditions require treatments that call for the injection of fluids into the human body. For example, severe trauma to the human body often involves significant loss of bodily fluids. Additionally, illnesses often cause diarrhea followed by dehydration and ion imbalance. In order to rehydrate the individual, injection of an intravenous saline or dextrose solution is required. Other medical applications (e.g., wound irrigation) require similar fluid purity levels.
- An example of the need for injection of fluids into the body is in the area of dialysis. Treatments for patients having substantially impaired renal function, or kidney failure, are known as “dialysis.” Either blood dialysis (“hemodialysis”) or peritoneal dialysis methods may be employed. Both methods essentially involve the removal of toxins from body fluids by diffusion of the toxins from the body fluids into a toxin free dialysis solution. Peritoneal dialysis can be performed without complex equipment and in a patient's home. In the peritoneal dialysis process, the patient's peritoneal cavity is filled with a dialysate solution. Dialysates are formulated with a high concentration of the dextrose, as compared to body fluids, resulting in an osmotic gradient within the peritoneal cavity. The effect of this gradient is to cause body fluids, including impurities, to pass through the peritoneal membrane and mix with the dialysate. By flushing the dialysate from the cavity, the impurities can be removed.
- Due to indirect contact with bodily fluids through bodily tissues, rather than direct contact with blood, the dextrose concentration needs to be considerably higher in peritoneal dialysis than in hemodialysis, and the treatment is generally more prolonged. Peritoneal dialysis may be performed intermittently or continuously. In an intermittent peritoneal dialysis (IPD) procedure, the patient commonly receives two liters of dialysate at a time. For example, in a continuous ambulatory peritoneal dialysis (CAPD) procedure, the peritoneal cavity is filled with two liters of dialysate and the patient is the free to move about while diffusion carries toxins into the peritoneal cavity. After about 4-6 hours, the peritoneum is drained of toxified dialysate over the course of an hour. This process is repeated two to three times per day each day of the week. Continuous Cycle Peritoneal Dialysis (CCPD) in contrast, involves continuously feeding and flushing dialysate solution through the peritoneal cavity, typically as the patient sleeps.
- Because peritoneal dialysates are administered directly into the patient's body, it is important that the dialysis solution maintains the correct proportions and concentrations of reagents. Moreover, it is impractical to formulate and mix dialysis solutions on site at the typical location of administration, such as the patient's home. Accordingly, peritoneal dialysates are typically delivered to the site of administration in pre-mixed solutions.
- Unfortunately, dialysis solutions are not stable in solutions over time. For example, dextrose has a tendency to caramelize in solution over time, particularly in the concentrations required in the peritoneal dialysis context. To prevent such caramelization, peritoneal dialysis solutions are typically acidified, such as with hydrochloric acid, lactate or acetate, to a pH between 4.0 and 6.5. The ideal pH level for a peritoneal dialysate, however, is between 7.2 and 7.4. While achieving the desired goal of stabilizing dextrose in solution, the pH of acidified peritoneal dialysis solutions tends to damage the body's natural membranes after extended periods of dialysis. Additionally, the use of acidified peritoneal dialysates tends to induce acidosis in the patient.
- Bicarbonates introduce further instability to dialysis solutions. The most physiologically compatible buffer for a peritoneal dialysate is bicarbonate. Bicarbonate ions react undesirably with other reagents commonly included in dialysate solutions, such as calcium or magnesium in solution, precipitating out of solution as insoluble calcium carbonate or magnesium carbonate. These insolubles can form even when the reactants are in dry form. When occurring in solution, the reactions also alter the pH balance of the solution through the liberation of carbon dioxide (CO2). Even in the absence of calcium or magnesium salts, dissolved sodium bicarbonate can spontaneously decompose into sodium carbonate and CO2, undesirably lowering the solution's pH level.
- Accordingly, a need exists for improved methods and devices for formulating solutions for peritoneal dialysis. Desirably, such methods and devices should avoid the problems of non-physiologic solutions and incompatibility of dialysate reagents, and also simplify transportation, storage and mixing of such dialysates. One aspect of this problem is the need for mechanisms for safely and completely mixing constituents of dialysates in diluent at the point of administration. Another aspect of this problem is the need for producing injectable quality water or other diluent at the point of administration.
- It is often advantageous to provide purified fluid independently of other constituents in the injected fluid. In many situations, independent provision of purified water simplifies transport and storage of solution constituents. In the case of peritoneal dialysis, preparing dialysate solution from dry reagents and independently provided pure water also minimizes the time for which unstable solutions must be stored prior to administration. Similarly, many other unstable solutions should be prepared soon before administration, preferably at the site of administration.
- On site purification of fluids is also advantageous in a number of other medical applications, including intravenous injection, intramuscular injection, orally administered fluids, wound irrigation, use in instrument cleaning solutions, and general employment by immuno-compromised individuals (e.g., AIDS patients, geriatrics, etc.).
- While separating provision of injectable quality fluid from other constituents can simplify transportation and delay production of unstable solutions, transporting purified water to the site of administration, even if produced and shipped separately from dry reagents, can represent considerable costs, as well as introducing opportunities for contamination. Transportation costs and contamination are particularly problematic when fluids are to be administered outside of a controlled hospital or clinic environment. Problems are even further exacerbated in lesser-developed countries, such as in the Indian subcontinent and Africa. Even in a hospital setting, the ability to convert available water into injectable quality water on site can reduce transportation and storage costs as well as avoiding the risk of contamination during transportation and storage.
- Therefore, a need exists for a method and apparatus that allow preparation of injectable quality fluid from available fluid. Desirably, the apparatus should be transportable and convenient for on-site use in remote locations.
- In satisfying the aforementioned needs, the embodiments described herein provide a portable apparatus and method for purifying fluid to levels suitable for medical applications, including injection into the human body.
- In accordance with one aspect of the present invention, a portable apparatus is provided for producing injectable quality fluid. The apparatus includes a housing that defines a fluid flow path from an inlet port to an outlet port. A depth filtration stage, an organic filtration component, a deionization resin bed and a permeable membrane are held within the housing along the fluid flow path. The permeable membrane has a porosity of less than about 0.5 μm and is configured to retain endotoxins.
- In accordance with another aspect of the present invention, a water purification pack for producing injectable quality water includes a container. The container defines a flow-through path from an inlet to an outlet with an average cross-sectional area of less than about 20 square inches. The container houses purification elements within the path, including a permeable membrane having a porosity of no more than about 0.5 μm. The purification elements provides a back-pressure low enough to allow fluid flow greater than about 30 L/min under a feed pressure of between about 5 psi and 10 psi.
- In accordance with another aspect of the invention, a method is provided for producing injectable quality of water. The method includes providing a portable purification pack with a housing surrounding purification elements in series. Non-sterile water is provided to an inlet of the housing under a feed pressure of less than about 20 psi. The water passes through the purification elements. Purified water exits from an outlet of the housing. The purified water has an organic content, conductivity, pH level and particulate contamination level suitable for injection into the human body.
- In accordance with another aspect of the invention, a method is provided for producing fluid for medical applications. The method includes providing a portable housing. Non-sterile fluid passes through the housing. Particulate contamination, organic matter, dissociated ions, microbes and endotoxins from the feed fluid are retained within purification elements in the housing. Fluid suitable for medical applications is then output from the housing.
- These and other aspects of the invention will be apparent to the skilled artisan in view of the Detailed Description and claims set forth below, and in view of the appended drawings, which are meant to illustrate and not to limit the invention, and wherein:
-
FIG. 1 is a schematic side perspective view of a system for producing peritoneal dialysate or other medical solutions; -
FIG. 2 is a schematic side sectional view of a fluid purification pack, constructed in accordance with one aspect of the present invention; -
FIG. 3 is a schematic side sectional view of a reagent cartridge for housing reagents of peritoneal dialysate; -
FIG. 4 shows the reagent cartridge ofFIG. 3 after partial dissolution of the reagents housed therein; -
FIG. 5 shows the reagent cartridge ofFIG. 3 after complete dissolution of the reagents housed therein; -
FIG. 6 is a schematic side sectional view of a reagent cartridge for housing reagents of peritoneal dialysate; -
FIG. 7 shows the reagent cartridge ofFIG. 6 after complete dissolution of the reagents housed therein; -
FIGS. 8A and 8B illustrate side sectional and plan views, respectively, of a downstream end of the water purification pack ofFIG. 2 ; -
FIGS. 9A and 9B illustrate side sectional and plan views, respectively, of an upstream end of the reagent cartridge ofFIG. 3 , configured to irreversibly connect with the water purification pack; and -
FIG. 10 is a side sectional view of a coupling between the water purification pack and reagent cartridge ofFIGS. 8 and 9 . - While the illustrated embodiments are described in the context of a particular application, i.e., peritoneal dialysis, the skilled artisan will find application for the apparatus and methods for producing injectable quality fluid in a variety of medical applications. Moreover, the apparatus and methods for producing “injectable quality” fluids will have applications beyond the medical field, wherever similarly pure water is desirable. The fluid purification unit described herein has particular utility when connected in series upstream of fluid collection/delivery devices, such as the illustrated mechanism for mixing dry reagent as purified diluent flows through.
- System for Preparing Peritoneal Dialysis Solution
-
FIG. 1 illustrates asystem 10 for producing solutions suitable for injection into the human body. A diluent orfluid purification pack 12, as described in more detail below, is connected upstream of areagent cartridge 14. Thecartridge 14, in turn, is in fluid communication with asolution reservoir 16 via atube 18. As also set forth in more detail below, purified diluent is provided from thepack 12 to thereagent cartridge 14, wherein the dry reagents are dissolved and solution is delivered to thereservoir 16. Alternatively, the solution can be delivered directly to the patient's body. - In the illustrated embodiment, the solution comprises peritoneal dialysis solution. The
cartridge 14 advantageously houses dry or lyophilized formulations of reagents suitable for peritoneal dialysis. Desirably, the solution is formed immediately prior to delivery to the patient's peritoneal cavity, such that the dialysate need not be stored in solution form for extended periods, and little opportunity exists undesirable reactions within the solution prior to delivery. - The
cartridge 14 defines fluid flow paths through the dry reagents, by way of porous elements therebetween, enabling dry storage in confined reagent beds while also enabling dissolution simply by passing diluent through the housing. Two preferred versions of thecartridge 14 are described in more detail with respect toFIGS. 3-7 , below. - The
diluent purification pack 12 of the illustrated embodiment is capable of on-site purification of locally available fluid, such as tap water from a municipal water source. The preferred water purification pack is described in more detail with respect toFIG. 2 below. - Water Purification Pack
- Referring to
FIG. 2 , the preferredfluid purification pack 12 is capable of purifying water or other liquid diluent to the standards required for injection into a patient, e.g., for peritoneal dialysis applications. Advantageously, available water, preferably potable water, can be introduced to the system, and is purified as it flows through the pack. The purified water can be delivered, for example, directly to the reagent cartridge 14 (FIG. 1 ), to a storage or collection container for short-term storage or transportation or direct connection to another delivery device, such as a wound irrigation pump. Accordingly, bulky purified water need not be stored long in advance of its need or transported great distances to the point of administration. Complex machinery for purifying water is also obviated. - In order to serve as a diluent for injection into the human body, or for similar applications, the independently provided water must be highly purified. The U.S. Pharmacopoeia provides processes for producing sterile water for injection. The
preferred water pack 12 also produces water of a quality suitable for injection, preferably equivalent to or surpassing the quality produced by the U.S. Pharmacopoeia processes. Water purified through the pack thus preferably meets or exceeds the U.S. Pharmacopoeia's standards for Sterile Water for Injection, including sterility, pH, ammonia, calcium, carbon dioxide, chloride, sulfate and oxidizable substances tests. In particular, injectable quality water or other fluid produced by the illustratedwater purification pack 12 exhibits the following characteristics: a very low level of total organic carbon, preferably less than about 1 ppm and more preferably less than about 500 ppb; low conductivity, preferably less than about 5.0μ Siemens (2.5 ppm) and more preferably less than about 2.0μ Siemens (1 ppm); near neutral pH, preferably between about 4.5 and 7.5, and more preferably between about 5.0 and 7.0; very low particulate concentration, preferably fewer than less than about 12 particles/mL of particles≧10 μm, more preferably less than about 6 particles/mL of such particles, and preferably less than about 2 particles/mL of particles≧25 μm, more preferably less than about 1 particle/mL of such particles; and low endotoxin levels, preferably less than about 0.25 endotoxin units (EU) per mL (0.025 ng/mL), more preferably less than about 0.125 EU/mL (0.0125 ng/mL) with a 10:1 EU/ng ratio. - Conventionally, purifying non-sterile fluid to such stringent quality standards, particularly for introduction into the human body, has called for extensive mechanical filtration and/or distillation, pumping, distribution and monitoring systems. These complex mechanisms can safely and economically produce large volumes of sterile water to injectable quality. Such mechanisms, however, occupy considerable space at a central location and necessitate even more space for storing purified water closer to the site of administration. Moreover, conventional water purification mechanisms are not conducive to employment in a portable apparatus for use in the field.
- U.S. Pat. No. 5,725,777 to Taylor discloses a portable apparatus for purifying water to injectable quality. The apparatus includes several stages for purification, including multistage depth prefiltering, ultrafiltration fibers, reverse osmosis fibers, ion exchange resin and activated carbon in that order.
- The reverse osmosis stage of Taylor '777 effectively purifies water to a high degree. Unfortunately, because reverse osmosis involves diffusing input water across a semi-permeable membrane, the rate of water production is very slow relative to the cross-section of the membrane. Even with the use of multiple reverse osmosis fibers with a high overall membrane surface area, diffusion is slow. In order to fully realize the advantages of portability, purified diluent should be rapidly produced at the time of administration. For acceptable rates using the apparatus of Taylor '777, however, high pressures (e.g., 40 to 75 psi) are applied across the semi-permeable membrane. Pumps and restrictor means for realizing these pressures reduce the versatility and portability of the overall system.
- In the illustrated embodiment, the water or
fluid purification pack 12 comprises ahousing 20 with anaxial inlet 22 andoutlet 24. Thehousing 20 defines a flow path between theinlet 22 andoutlet 24, with multiple purification stages along the flow path. Thepack 12 is thus designed to purify fluid in the course of traveling, preferably in a linear path, through thehousing 20. - The
housing 20 is preferably formed of a suitable polymer, particularly polycarbonate, which aids in purifying water by binding endotoxins through charge interactions. Endotoxins are the organic byproduct of dead microorganisms, particularly the outer cell wall of bacteria. Although the term endotoxin is occasionally used to refer to any “cell-associated” bacterial toxin, it primarily refers to the lipopolysaccharide complex associated with the outer envelope of Gram-negative bacteria such as E. coli, Salmonella, Shigella, Pseudomonas, Neisseria, Haemophilus, and other leading pathogens. In high enough concentrations, particularly in critical applications such as intravenous injection, this organic matter can be toxic. - The
pack 12 is configured for convenient portability. The skilled artisan will appreciate the fact that different sizes will safely produce different amounts of purified water. Thus, for an embodiment optimized for safely purifying 10 L of water, the outside dimensions of thehousing 20 preferably include a length of less than or equal to about 6 inches frominlet 22 tooutlet 24, and a width (diameter in the illustrated embodiment) of less than or equal to about 5 inches. The illustratedhousing 20, designed for safely purifying 2 L of water, has a length of about 3 inches and a diameter of about 2.25 inches. Preferably, therefore, thefluid purification pack 12 has a cross-sectional area of less than about 20 sq. inches, more preferably less than about 4 sq. inches. Despite this small cross-section, the illustratedpack 12 can achieve high flux rates under pressures as low as about 5-10 psi. - The
fluid purification pack 12 is also preferably configured to deliver a unit dose of purified fluid. Thepack 12 thus is preferably designed for one-time use and to be discarded thereafter. As such, the sterility of thepack 12 can be assured, since thepack 12 will not be reused after seals at theinlet 22 andoutlet 24 are broken. Several of the features described hereinbelow discourage or prevent recharging thewater pack 12 for repeated use, as will be understood by the skilled artisan. - Downstream of the
inlet 22 is adepth filter 26. The porosity limit of the illustrateddepth filter 26 preferably ranges from about 1 micron (μm) to 10 μm, most preferably about 1 μm. Thedepth filter 26 is preferably formed of a porous polypropylene mesh in multiple layers, particularly two to four layers. Alternatively, the commercially available cellulose-based depth filters can be employed, as will be understood by one of ordinary skill in the art. In still other arrangements, ceramic or other known particle filtration material can be employed. Most preferably, thedepth filter 26 comprises a series of depth filters (not shown) that successively filter out smaller and smaller particles. In the illustrated embodiment, four successive depth filters are included within thedepth filtration stage 26, having porosities of about 100 μm, 40 μm, 10 μm and 1 μm in sequence from upstream end to downstream end. - Downstream of the
depth filter 26 is anorganic filtration stage 28, which can comprise a bed of granular carbon. In the illustrated embodiment, the organic filtration stage comprises a resin bed treated for retention of organic contaminants. The illustrated embodiment incorporates a form of styrene divinylbenzene commercially available from Rohm & Haas of Philadelphia, Pa. under the trade names Ambersorb 563. This component removes certain residual organic contaminants, such as endotoxins, as well as commonly used additives placed in municipally treated waters (e.g., chlorine, trihalomethanes and chloramine). - Adjacent to the downstream end of the
organic filtration stage 28 is arestraint 30. Therestraint 30 is a filter of controlled porosity, preferably also comprising a polypropylene mesh with a porosity of about 1-10 microns, more preferably about 1 micron. This component prevents passage of particulates shed by theorganic filtration component 28, as well as providing a secondary assurance that insoluble particulates do not pass further through the water purification pack. - Adjacent to the downstream side of the
restraint 30 is a deionization stage, preferably comprising abed 32 of deionization resin beads. Theresin bed 32 more preferably comprises a mixture of pharmaceutical grade resins with strong anion exchanger (cation-impregnated) and strong cation exchanger (anion-impregnated) chemistries, binding dissociable ions and other charged particles with a very high affinity. In the illustrated embodiment, theresin bed 32 comprises mixed anion- and cation-impregnated resin beads with weakly associated hydrogen or hydroxyl groups, respectively. The ion exchange resins of the preferred embodiment comprise styrene divinyl benzene. Such resins are available, for example, from Rohm & Haas of Philadelphia, Pa. under the trade name IRN 150, or from Sybron of Birmingham, N.J. under the trade name NM60. Cation exchangers exchange hydrogens for any dissolved cations in the diluent. Common dissolved cations include sodium (Na+), calcium (Ca2+) and aluminum (Al3+). The anion exchange resins exchange hydroxyl ions for any anions present in an aqueous solution. Common anions include chloride (Cl−) and sulfides (S2−). Theresin bed 32 additionally retains some endotoxins that escape the upstream filtration components. The skilled artisan will recognize other types of ion-exchange resins that could also be utilized in this stage. - The preferred
mixed resin bed 32 simplifies and provides a morecompact pack 12 than more conventional ion exchange columns, wherein anion and cation exchangers are separated. Moreover, themixed bed 32 arrangement prevents recharging the ion exchange resin by back-flushing, thus discouraging re-use and maintaining sterility of the unit. - Downstream of the
deionization resin bed 32 are adeionization bed restraint 34 and aterminal filter element 36, in sequence. Therestraint 34 preferably comprises the same polypropylene mesh utilized for the illustrateddepth filter 26 andcarbon bed restraint 30. Theresin bed restraint 34 serves to prevent passage of deionization bed fragments or fines, as well as any other particulates that have escaped theupstream filters restraint 34 also serves to protect thefilter element 36 downstream of therestraint 34. - The
terminal filter element 36 comprises a permeable membrane, preferably a microfiltration or ultrafiltration membrane, depending upon the application. The term “terminal,” as utilized in this context, refers to the filtration element with the lowest porosity, and not the physical location. Typically, however, the terminal filter will be immediately adjacent the outlet, as shown, such that large particulates are filtered out by courser filtration elements upstream of the terminal filter. Theterminal filter 36 preferably has a porosity of at most about 0.5 μm, and none preferably less than about 0.22 μm. - For applications in remote locations where water is untreated or insufficiently treated, an ultrafiltration membrane is most preferable. Nominal porosity of between about 10,000 and 30,000 molecular weight cut-off desirably filters out viruses prevalent in such locations, such as hepatitis, rota virus, polio, etc. Nominal cut-off for the illustrated embodiment is between about 15,000 and 25,000 MW. While endotoxins (complex lipopolysaccaride) generally aggregate into complexes of greater than about 1,000,000 molucular weight, an ultrafiltration membrane can retain even a single unit of endotoxin (about 15,000 molecular weight).
- For employment in more developed locations, where treated water is available (e.g., municipal water in most American cities), the
water purification pack 12 need not filter out pathogenic viruses. Accordingly, for such uses theterminal filter 36 comprises a microfiltration membrane. Advantageously, the higher porosity of a microfiltration membrane allows a greater flow rate for a given feed pressure or a lower feed pressure for a given flow rate. The microfiltration membrane preferably has a porosity of lower than about 0.5 μm, and more preferably comprises a 0.22 μm or finer filter, and most preferably has a porosity of about 0.20 μm or finer. Desirably, theterminal filter 36 has enhanced endotoxin binding characteristics and is preferably chemically treated to incorporate a quaternary amine exchanger (QAE) to bind endotoxins. Such endotoxin binding membranes are available under the trade name HP200 from the Pall Specialty Materials Co. Most preferably, theterminal filter 36 comprises two successive QAE-treated 0.20 μm permeable membranes, ensuring adequate endotoxin retention. Despite a high flux rate compared to ultrafiltration membranes, therefore, theterminal filter 36 incorporating a microfiltration membrane removes endotoxins as well as microbes and particulate matter of less than 1 μm from diluent passing therethrough. In fact, challenge water with endotoxin levels as high as 1,000 ng/mL have been purified through the illustratedpack 12 to below the current detection limit (0.006 ng/mL). - The purification stages within the water purification pack are thus such that water passing through the
pack 12 and exiting thehousing outlet 24 is of a purity level safe for injection into the human body (following the addition of appropriate salts for physiologic solutions). Preferably, effluent water conforms to the purity levels set forth above. It will be understood, of course, that while safe enough for injection, the fluid may actually be employed for alternative medical applications, such as wound irrigation, use in instrument cleaning solutions, and general employment by immuno-comprised individuals (e.g., AIDS patients, geriatrics, etc.). - Desirably, the
water purification pack 12 includes anupstream cap 38 over thehousing inlet 22, and adownstream cap 40 over thehousing outlet 24. The sterility of the purification elements housed within thehousing 20 is thus maintained until use. As will be understood in the art, theinlet 22 andoutlet 24 can be provided with threads or Luer-type fittings (seeFIGS. 8-10 ) to mate with upstream and downstream elements in the peritoneal dialysate delivery system 10 (FIG. 1 ). - The sterility and efficacy of the
water purification pack 12 is also reinforced by features discouraging re-use of the water pack. As previously noted, theresin bed 32 preferably comprises a mixed bed of anion- and cation-exchangers. Thus, themixed bed 32 cannot be recharged by traditional backflushing techniques, since regeneration of the cation-exchanger would result in exhaustion of the anion exchanger and vice versa. - Additionally, the water purification pack is preferably configured to irreversibly connect with a downstream collection device. In one preferred arrangement, the
housing outlet 24 is welded or otherwise integrally connected with a collection tube leading to a collection bag or other container. When water is purified by passing through thehousing 22 and fills the downstream collection container, the preferred plastic tubing is simultaneously cut and cauterized to seal the tube downstream of theoutlet 24, preventing re-use of thewater pack 12. - With reference to
FIGS. 8 and 9 , in another preferred arrangement, theoutlet 24 is irreversibly connectable with thedownstream reagent cartridge 14. Thewater pack outlet 24 and thereagent cartridge inlet 52 thus have interlocking mechanisms that are irreversible without damage to the mechanisms. - In the illustrated embodiment, the
water pack housing 20 includes acylindrical collar 42 surrounding theoutlet 24, the collar having outer ratchetingteeth 44. Thereagent pack 14 includes a similarcylindrical collar 46 surrounding theinlet 52, and thecollar 46 includesinternal ratchet teeth 48. Theouter collar 46 of thereagent pack 14 is sized to fit over theouter collar 42 of thewater pack 12. The ratchetingteeth teeth - Accordingly, the locking mechanism must be broken or otherwise damaged to separate the used
water pack 12 from thereagent cartridge 14. Such damage or breakage minimizes the risk of accidentally re-using a spentwater pack 12. The skilled artisan will readily appreciate that similar irreversible locking mechanisms can be utilized with other collection or delivery devices downstream of the water purification pack. The skilled artisan will also recognize other suitable irreversible locking mechanisms for discouraging re-use. - Single-Bed Reagent Cartridge
-
FIGS. 3-5 illustrate a single-bed reagent cartridge 14 for use with the water purification pack. The figures illustrate various stages of dissolution, as will be better understood from the methods of operation discussed hereinbelow. -
FIG. 3 shows a fully chargedreagent cartridge 14, in accordance with the first embodiment. Thecartridge 14 comprises rigidwalled housing 50 with aninlet port 52 at an upstream end, and anoutlet port 54 at a downstream end. Within the housing, a number of porous elements define a fluid flow path between theinlet port 52 and theoutlet port 54. - The
housing 50 is preferably transparent or translucent, advantageously enabling the user to observe the operation of the device and complete dissolution of reagents prior to use of a produced solution, as will be apparent from the discussion of the method of operation, discussed hereinbelow. Examples of translucent and transparent polymers are polypropylene, polycarbonate and many other well-known materials. - Within the
housing 50, immediately downstream of theinlet port 52, is aninlet frit 56, which serves as a safety filter to contain any reagent which escapes the restraints described below. An outlet frit 58 serves a similar function immediately upstream of theoutlet 54. Desirably, theinlet frit 56 and the outlet frit 58 comprise porous elements having a porosity smaller than the smallest particle of the reagents housed within thecartridge 14. Thefrits - Downstream of the
inlet frit 56 is an upstreamreagent compression component 60. Similarly, upstream of the outlet frit 58 is a downstreamreagent compression component 62. Thecompression components compression components compression components housing 50 are arranged such that thecompression components compression components housing 50. Desirably, the pressure exerted is between about 50 grams per sq. inch and 2,000 grams per sq. inch, more preferably between about 300 grams per sq. inch and 900 grams per sq. inch. - It will be understood that, in other arrangements, metal or polymer coiled springs and porous plates can serve the same function. Such alternative compression components are disclosed, for example, with respect to
FIGS. 12-15 ; Col. 9, lines 8-53 of U.S. Pat. No. 5,725,777, the disclosure of which is incorporated herein by reference. Another preferred compression component is disclosed in U.S. provisional application No. 60/132,088, filed Apr. 30, 1999, the disclosure of which is hereby incorporated by reference. It will also be understood, in view of the discussion below, that a single compression component can serve the function of the illustrated two compression components. Two components exerting pressure on either side of a reagent bed 64 (described below), however, has been found particularly advantageous in operation. - A
single reagent bed 64 is situated between thecompression components reagent bed 64 is desirably sandwiched between anupstream reagent restraint 66 and adownstream reagent restraint 68. Theupstream reagent restraint 66 is thus positioned between thereagent bed 64 and theupstream compression component 60, while thedownstream reagent restraint 68 is positioned between thereagent bed 64 and thedownstream compression component 62. - The
restraints frits - Additionally, the
restraints housing 50, forming an effective seal against reagent particulates escaping around therestraints - The
reagent bed 64 comprises a complete formulation of dry or lyophilized reagents required to produce a peritoneal dialysis solution. In the illustrated single-bed embodiment, the reagent bed 65 is a mixture of compatible reagents, such as will not exhibit spontaneous chemical reaction from prolonged contact in their dry form. Accordingly, a buffering agent such as an acetate or lactate, and particularly sodium lactate, is employed in place of a bicarbonate. Further reagents include electrolytes, such as sodium chloride, magnesium chloride, potassium chloride and calcium chloride; a sugar, preferably dextrose; and an acid, particularly citric acid. Advantageously, the acid component of the reagent bed 65 can be lower than conventional solutions, since storage in dry form alleviates the tendency for dextrose caramelization. - The illustrated
housing 50 holds reagents sufficient to produce 2 liters of a typical peritoneal dialysate solution. Accordingly, thereagent bed 64 holds the following reagents:TABLE I Dry Reagent Constituents Mass Dry Volume Calcium chloride 514 mg Negligible Magnesium chloride 101.6 mg Negligible Sodium lactate 8.96 g 24 mL Sodium chloride 10.76 g 22 mL Dextrose 50 g 70 mL Total 70 g 116 mL - The dry volume of the above-listed reagents, which can produce 2 L of 2.5% dextrose peritoneal dialysate, is thus about 100 mL. The
housing 50 for such a formulation need only be about 125% to 500% of the dry reagent volume, more preferably about 150% to 200%, depending upon the selectedcompression components housing 50 is about 2″ in diameter and about 3″ in height, thus occupying about 175 mL. Thecartridge 14 thus represents a much smaller and more stable form of dialysate for storage and transport, compared to 2 L of prepared solution. If a smaller or larger volume of solution is desired, the skilled artisan can readily determine the proportionate weight and volume of dry reagents required in thereagent bed 64, such as for producing 1 L, 3 L, 6 L, 10 L, etc. Similarly, the skilled artisan can readily determine the proportions of reagents desirable for 1.5% dextrose dialysate, 4% dextrose dialysate, etc. - An
inlet port cover 70 and an outlet port cover 72 cover thehousing inlet port 52 andoutlet port 54, respectively. The port covers 70, 72 advantageously seal out moisture and prevent destabilization of the dry reagents housed within during transport and storage. As with the water purification pack, theinlet port 52 andoutlet port 54 can be configured with threaded or Luer-type connection fittings. In the illustrated embodiment, theinlet port 52 is configured to mate with theoutlet 24 of the water purification pack 12 (FIG. 2 ), while theoutlet port 54 is configured to mate with the downstream tube 18 (seeFIG. 1 ). - Double-Bed Reagent Cartridge
-
FIGS. 6 and 7 illustrate a double-bed reagent cartridge 14′.FIGS. 6 and 7 illustrate thecartridge 14′ in fully charged and fully depleted conditions, respectively, as will be better understood from the methods of operation discussed hereinbelow. - With reference initially to
FIG. 6 , thehousing 50 of the double-bed reagent cartridge 14′ is preferably similar to that of the first embodiment, such that like reference numerals are used to refer to like parts. Thus, thehousing 50 defines aninlet port 52 andoutlet port 54, and contains porous elements between theinlet port 52 andoutlet port 54, such as to define a fluid flow path through thehousing 50. Specifically, thehousing 50 contains anupstream frit 56,upstream compression component 60,upstream reagent restraint 66,downstream reagent restraint 68,downstream compression component 62 anddownstream frit 58. Each of these elements can be as described with respect to the previous embodiment. - Unlike the single-
bed cartridge 14 ofFIGS. 3-5 , however, multiple reagent beds are confined between theupstream restraint 66 anddownstream restraint 68. In particular, aprimary reagent bed 80 and asecondary reagent bed 82 are shown in the illustrated embodiment, separated by at least one restraint. In the illustrated embodiment, thereagent beds intermediate restraint 84 and secondintermediate restraint 86, as well as anintermediate compression component 88 between theintermediate restraints - Accordingly, the
primary reagent bed 80 is confined betweenupstream restraint 66 and the firstintermediate restraint 84, while thesecondary reagent bed 84 is similarly confined between the secondintermediate restraint 86 and thedownstream restraint 68. The intermediatereagent bed restraints beds intermediate reagent restraints frits downstream reagent restraints intermediate compression component 88 can have the same structure as the upstream anddownstream compression components - Each of the
intermediate compression component 88 and theintermediate reagent restraints primary reagent bed 80 from thesecond reagent bed 82. Due to the selected porosity of the elements, particularly theintermediate restraints reagent beds - The illustrated double-bed embodiment therefore enables separate storage of different reagents within the
same housing 50. A complete formulation of the dry reagents required to produce a peritoneal dialysis solution may contain reagents that react undesirably when exposed to one other for prolonged periods of time, in either dry or liquid forms, as noted in the Background section. For example, bicarbonates are preferred, physiologically compatible buffering agents for peritoneal dialysis, but tend to be very reactive with typical salts in the dialysate formulation, such as calcium chloride or magnesium chloride. The reactions form insoluble calcium carbonate or magnesium carbonate, and also liberate CO2. Because of the potential reactivity of incompatible reagents, it is preferable to separately store these reagents within thedevice housing 50. - Separate storage is accomplished by separating reagents into compatible groupings, which are then placed in separate compartments within the housing. The compartments are represented, in the illustrated embodiment, by the
primary reagent bed 80 and thesecondary reagent bed 82. The potentially reactive reagents are thereby constrained from movement through the housing, when maintained in their dry form, byreagent bed restraints reagent beds reagent bed restraints - In the illustrated embodiment, the
primary reagent bed 80 is a reagent mixture, preferably comprising: electrolytes, particularly sodium chloride, potassium chloride, calcium chloride and magnesium chloride; a sugar, particularly dextrose. In other arrangements, theprimary reagent bed 80 can also comprise a buffer. - The
secondary reagent bed 82 can contain at least one component that is unstable in the presence of at least one component in theprimary reagent bed 80. Advantageously, thesecondary reagent bed 82 contains a bicarbonate, such as sodium bicarbonate. Because the bicarbonate is separated from calcium chloride and magnesium chloride, the reagents do not react to form insoluble precipitates. - The skilled artisan will readily appreciate that, in other arrangements, the
primary reagent bed 80 can contain the bicarbonate if thesecondary bed 82 contains calcium chloride and/or magnesium chloride. In still other alternatives, other incompatible reagents for medical solutions can be similarly separated into reagent beds within the same housing. Moreover, three or more reagent beds can be utilized to separate multiple incompatible reagents. - The illustrated
housing 50 holds reagents sufficient to produce 2 liters of a typical peritoneal dialysate solution. Accordingly, thereagent beds TABLE II Mass Dry Volume Primary Reagent Bed Calcium chloride 514 mg Negligible Magnesium chloride 101.6 mg Negligible Sodium chloride 10.76 g 22 mL Dextrose 50 g 70 mL Subtotal 61 92 mL Secondary Reagent Bed Sodium bicarbonate 6.64 g 6.1 mL Total 68 g 98 mL - The dry volume of the above-listed reagents, which can produce 2 L of 2.5% dextrose peritoneal dialysate, is thus about 98 mL. As with the previously described single-bed embodiment, the total volume of the
cartridge 14′ is preferably between about 125% and 500%, and more preferably 150% and 200%, of the dry reagent volume. As also noted above, the skilled artisan can readily determine the proportionate weights and volumes of dry reagents required for forming other peritoneal dialysate solutions, such as 1.5% dextrose dialysate, 4% dextrose dialysate, etc. - Notably, the double-bed cartridge utilizes bicarbonate as the buffer, and omits the need for physiologically damaging acid by enabling production of a physiologic solution.
- Method of Operation
- In operation, purified diluent is provided to a
reagent cartridge system 10 ofFIG. 1 , such that the purified diluent is produced on site and need not be produced remotely and transported, significantly reducing the cost of transportation. - Accordingly, with reference to
FIG. 2 , diluent in the form of available water is first provided towater purification pack 12 ofFIG. 2 . Pressure commonly found in municipal water systems is sufficient to feed the water through thepurification pack 12. Alternatively, a hand pump or large syringe can be supplied with a measured volume of water, and water hand-pumped therefrom into thepurification pack 12. Feed pressure is preferably less than about 20 psi. Fluid flux through the purification pack 12 (with a feed pressure of about 5-10 psi) is preferably at least about 30 mL/min, and more preferably at least about 90 mL/min through thepack 12. - The diluent enters the
inlet 22 and passes throughdepth filter 26, where particulates larger than about 1 micron are filtered out. Thedepth filter 26 retains insoluble particulates and microbes greater than the pore sizes of the successive layers in this component. Depth filtration is extremely effective in removing contaminants such as asbestos fibers and similarly sized particles. - Filtered diluent continues downward through
organic filtration stage 28, where residual organics such as endotoxins and additives such as chlorine, chloramine and trihalomethanes are adsorbed. Additionally, some inorganic materials are removed in the process. Carbon is effective at adsorbing many types of chemicals, it is especially known for its power in adsorbing organic compounds. Carbon's particular affinity for organics is due to its non-polar nature. Carbon is also somewhat effective in adsorbing metals and other inorganics. The illustrated resin has similar absorption characteristics. - After being additionally purified by the
organic filtration stage 28, the partially purified diluent passes through therestraint 30 and into the ion-exchange resin bed 32. Dissociated ions and other charged particulates in solution bind to the resins. Some endotoxins that have escaped the upstream components are also retained in theresin bed 32. - After passing through the
resin bed restraint 34, which retains the contents of theresin bed 34, the diluent is further purified through theterminal filter element 36. In one embodiment, as previously noted, theterminal filter 36 comprises an ultrafiltration membrane with a nominal cut-off of between about 10,000 and 30,000 molecular weight. Depending upon the density of pores, 5-10 psi feed pressure can produce a flux of between about 35 mL/min and 100 mL/min through such an ultrafiltration membrane. In another embodiment, thefilter 36 comprises at least one and preferably two microfiltration membranes of a very fine porosity (e.g., about 0.22 μm or finer), each including chemical treatment with a quaternary amine exchanger for binding residual endotoxins. The flux rate for a device with the microfiltration membrane can be more that twice that of an ultrafiltration membrane with equivalent pore density. - The multiple filtration and chemical binding components of the
water purification pack 12 thus ensure removal of particulate, ionic and organic contaminants from the diluent as it passes through thepack 12. Endotoxins, including organic matter such as cell walls from dead bacteria, can be particularly toxic. Highly purified diluent, sufficient to comply with or exceed FDA and U.S. Pharmacopoeia water quality standards for “sterile water for injection,” exits theoutlet 24, but without the need for reverse osmosis. - With reference to
FIG. 1 again, purified diluent then passes from thewater purification pack 12 to a collection/delivery device. As noted above, in one embodiment, the downstream device can comprise a simply storage container, such as a plastic bag. In the illustrated embodiment, the storage/delivery device comprises thereagent cartridge 14. Desirably, the downstream storage/delivery device is irreversibly fixed to thewater pack outlet 24, either integrally or through a locking mechanism. -
FIGS. 3-5 illustrate dissolution ofdry reagent 64 as diluent passes through the single-bed reagent cartridge 14 for the peritoneal dialysis. While illustrated cross-sectionally, it will be understood that the preferred transparent ortranslucent housing 50 enables the user to similarly observe dissolution of thereagent bed 64 as solvent or diluent passes therethrough. Additionally, the user can observe whether insoluble precipitates are present within the reagent bed, prior to employing thecartridge 14. Advantageously, gravitational force is sufficient to draw the water through thecartridge 14. - Referring initially to
FIG. 3 , purified diluent enters thecartridge 14 through theinlet port 52. Preferably, purified diluent is fed directly from thewater purification pack 12. “Directly,” as used herein, does not preclude use of intermediate tubing, etc, but rather refers to the fact that water is purified on site immediately prior to solution formation, rather remotely produced and shipped. It will also be understood, however, that the illustrated reagent cartridge will have utility with other sources of sterile diluent. - The diluent passes through the
porous inlet frit 56 and theupstream compression component 60. In the illustrated embodiment, thecompression component 60 is a porous, open-celled foam, which readily allows diluent to pass therethrough. The diluent then passes through theupstream reagent restraint 66 to reach thedry reagent bed 64. In addition to retaining the dry reagents in thebed 64, thefrit 56 andrestraint 66 facilitate an even distribution of water flow across the sectional area of thehousing 50. - As the solution passes through interstitial spaces in the
bed 64, the dry reagents are eroded, preferably dissolved, and carried by the diluent through thedownstream reagent restraint 68, thedownstream compression component 44 and theoutlet frit 58, exiting throughoutlet 24. The solution passes through thetube 18 into the collection reservoir 16 (seeFIG. 1 ) and then into the peritoneal cavity of a patient. - Referring to
FIG. 4 , as the reagents are dissolved, the volume of thereagent bed 64 is reduced, as can be seen from a comparison ofFIG. 4 withFIG. 3 . Thecompression components reagent bed 64. As dry reagent is dissolved, the compressive force packs the reagents close together. Such continuous packing prevents expansion of interstitial spaces as the reagent particles are dissolved. Without the compressive force, the interstitial spaces between the reagent particles tend to expand into larger channels within thereagent bed 64. These channels would serve as diluent flow paths, which would permit a large volume of diluent to flow through thebed 64 with minimal further dissolution. Significant portions of the bed would be by-passed by these channels, and dissolution would be slow and inefficient. Applying continuous compression to the beds minimizes this problem by continuously forcing the reagent particles together as the bed dissolves, ensuring continuous, even exposure of the diluent to the reagents of thebed 64. - Though two
compression components reagent bed 64 from two sides, it will be understood that a single compression component can also serve to keep theregent beds 64 compacted. Moreover, though illustrated in an axial arrangement, such that diluent flows through thecompression components - The compressive force of the
preferred compression components housing 50, additionally aids in maintaining the planar configuration of thereagent restraints reagent bed 64, even as thecompression components restraints bed 64 until dissolved. - With reference to
FIG. 5 , dissolution continues until the reagent bed is depleted and therestraints housing 50 into the reservoir 16 (FIG. 1 ) until the appropriate concentration of peritoneal dialysate solution is formed. For example, in the illustrated embodiment, 2 liters of diluent should be mixed with the contents of thereagent bed 64. Accordingly, 2 liters of diluent are passed through thehousing 50. The contents are typically fully dissolved by the time about 1.5 liters has passed through the housing, but diluent can continue to flow until the appropriate final concentration is reached in the reservoir. Alternatively, a concentrate can be first formed and independently diluted. - Advantageously, the illustrated apparatus and method can form peritoneal dialysis solution simply by passing water through the
cartridge 50, without complex or time consuming mixing equipment. The solution can thus be formed on-site, immediately prior to delivery to the peritoneal cavity, such that the dialysate need not be shipped or stored in solution form. Accordingly, a low acid level is possible without undue risk of dextrose carmelization. Conventionally, a pre-formed dialysis solution formed has a pH between about 4.0 and 6.5, and the exemplary reagent mix of Table I produces a conventional solution with pH of about 5.2. Solution produced from the illustrated single-bed cartridge ofFIGS. 3-4 , however, can have lower acidity, since dextrose does not sit in solution for extended periods of time. Accordingly the pH level is preferably between about 6.0 and 7.5, more preferably about 7.0. - Referring to
FIGS. 6 and 7 , the double-bed reagent cartridge 14′ operates in similar fashion. Purified diluent is fed to thehousing inlet 52, and passes through theinlet frit 56, theupstream compression component 60, theupstream restraint 66, and into theprimary reagent bed 80. Dissolution of reagents in theprimary bed 80 forms a solution which passes on through the firstintermediate restraint 84, theintermediate compression component 88 and the secondintermediate restraint 86. Reagents in thesecondary bed 82 then also dissolve into the diluent, and the enriched solution continues on through thedownstream reagent restraint 68, thedownstream compression component 62 and theoutlet frit 58. A complete solution thus exits theoutlet port 54. - As in the previous embodiment, the
regent beds compression components bed intermediate compression component 88, can accomplish this function, while advantageously also separating the incompatible reagent beds. Additionally, the compression component need not be axially aligned with the reagent beds, but could instead surround or be surrounded by the reagent beds, in which case the compression components would preferably be outside the diluent flow path. - Advantageously, the illustrated embodiments provide stable, dry forms of peritoneal dialysis solutions. Storage and transport of the reagent cartridges of the illustrated embodiments represents considerable cost savings over storage and transport of prepared peritoneal dialysate solutions. Dry or lyophilized reagents are moreover more stable than solution, and therefore less harmful to the patient.
- While the storage and transport of dry reagents is generally recognized as advantageous, practical application has been difficult. The described embodiments not only provide transport and storage, but additionally provide integrated mechanisms to ensure complete dissolution of the dry reagents. Continuous compression of the reagent bed(s) during dissolution, combined with the transparent windows allowing real time viewing of the dissolution, ensure rapid, complete and verifiable dissolution of the reagents. Thus, the preferred embodiments can be utilized on site, even in the home, without requiring complex mixing and/or analytical tools.
- Moreover, the illustrated embodiments facilitate a wider practicable range of reagents. For example, physiologically compatible bicarbonate can be employed along with calcium and magnesium. Separate storage and solution preparation only immediately prior to administration enables this combination. High dextrose solutions, as appropriate for peritoneal dialysis, can be employed without acidic buffers, such that physiologically compatible pH levels can be practically obtained, preferably between about 4.0 and 7.5, and more preferably between about 6.0 and 7.5. The reagents listed in Table II produce a solution with a pH of about 7.0.
- The illustrated
fluid purification pack 12 is also a compact, conveniently transportable device that facilitates on-site production of injectable quality fluid from available fluid. Advantageously, despite a small size and low feed pressure, thepack 12 rapidly provides on-site, injectable quality water as input water flows linearly from inlet to outlet. Apermeable terminal filter 36, represents the lowest porosity element in thepack 12. In contrast to semi-permeable, osmotic membranes, this element facilitates this high flux at low pressures while still retaining extremely fine particles and toxins. - Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will become apparent to those of ordinary skill in the art in view of the disclosure herein. Accordingly, the present invention is not intended to be limited by the recitation of preferred embodiments, but is intended to be defined solely by reference to the dependent claims.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/997,096 US20050113796A1 (en) | 1999-03-26 | 2004-11-09 | Water purification pack |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/277,448 US6274103B1 (en) | 1999-03-26 | 1999-03-26 | Apparatus and method for preparation of a peritoneal dialysis solution |
US09/364,631 US6719745B1 (en) | 1999-03-26 | 1999-07-30 | Water purification pack |
US10/339,702 US6814724B2 (en) | 1999-03-26 | 2003-01-08 | Water purification pack |
US10/997,096 US20050113796A1 (en) | 1999-03-26 | 2004-11-09 | Water purification pack |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/339,702 Continuation US6814724B2 (en) | 1999-03-26 | 2003-01-08 | Water purification pack |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050113796A1 true US20050113796A1 (en) | 2005-05-26 |
Family
ID=23060912
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/277,448 Expired - Fee Related US6274103B1 (en) | 1999-03-03 | 1999-03-26 | Apparatus and method for preparation of a peritoneal dialysis solution |
US09/364,631 Expired - Fee Related US6719745B1 (en) | 1999-03-03 | 1999-07-30 | Water purification pack |
US09/908,785 Expired - Fee Related US6426056B2 (en) | 1999-03-03 | 2001-07-18 | Apparatus and method for preparation of a peritoneal dialysis solution |
US10/210,422 Expired - Fee Related US6623709B2 (en) | 1999-03-03 | 2002-07-30 | Apparatus and method for preparation of a peritoneal dialysis solution |
US10/339,702 Expired - Fee Related US6814724B2 (en) | 1999-03-26 | 2003-01-08 | Water purification pack |
US10/664,215 Expired - Fee Related US6986872B2 (en) | 1999-03-03 | 2003-09-16 | Apparatus and method for preparation of a peritoneal dialysis solution |
US10/997,096 Abandoned US20050113796A1 (en) | 1999-03-26 | 2004-11-09 | Water purification pack |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/277,448 Expired - Fee Related US6274103B1 (en) | 1999-03-03 | 1999-03-26 | Apparatus and method for preparation of a peritoneal dialysis solution |
US09/364,631 Expired - Fee Related US6719745B1 (en) | 1999-03-03 | 1999-07-30 | Water purification pack |
US09/908,785 Expired - Fee Related US6426056B2 (en) | 1999-03-03 | 2001-07-18 | Apparatus and method for preparation of a peritoneal dialysis solution |
US10/210,422 Expired - Fee Related US6623709B2 (en) | 1999-03-03 | 2002-07-30 | Apparatus and method for preparation of a peritoneal dialysis solution |
US10/339,702 Expired - Fee Related US6814724B2 (en) | 1999-03-26 | 2003-01-08 | Water purification pack |
US10/664,215 Expired - Fee Related US6986872B2 (en) | 1999-03-03 | 2003-09-16 | Apparatus and method for preparation of a peritoneal dialysis solution |
Country Status (1)
Country | Link |
---|---|
US (7) | US6274103B1 (en) |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060180550A1 (en) * | 2005-02-16 | 2006-08-17 | Metal & Arsenic Removal Technology | Portable water purifier |
US20120012539A1 (en) * | 2010-01-08 | 2012-01-19 | Qiagen Gaithersburg Inc. | Water treatment apparatus and method for using same |
US9144640B2 (en) | 2013-02-02 | 2015-09-29 | Medtronic, Inc. | Sorbent cartridge configurations for improved dialysate regeneration |
US9192707B2 (en) | 2011-04-29 | 2015-11-24 | Medtronic, Inc. | Electrolyte and pH monitoring for fluid removal processes |
US9289165B2 (en) | 2005-02-07 | 2016-03-22 | Medtronic, Inc. | Ion imbalance detector |
US9456755B2 (en) | 2011-04-29 | 2016-10-04 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
US9526822B2 (en) | 2013-02-01 | 2016-12-27 | Medtronic, Inc. | Sodium and buffer source cartridges for use in a modular controlled compliant flow path |
US9707330B2 (en) | 2011-08-22 | 2017-07-18 | Medtronic, Inc. | Dual flow sorbent cartridge |
US9707328B2 (en) | 2013-01-09 | 2017-07-18 | Medtronic, Inc. | Sorbent cartridge to measure solute concentrations |
US9713665B2 (en) | 2014-12-10 | 2017-07-25 | Medtronic, Inc. | Degassing system for dialysis |
US9713668B2 (en) | 2012-01-04 | 2017-07-25 | Medtronic, Inc. | Multi-staged filtration system for blood fluid removal |
US9827361B2 (en) | 2013-02-02 | 2017-11-28 | Medtronic, Inc. | pH buffer measurement system for hemodialysis systems |
US9848778B2 (en) | 2011-04-29 | 2017-12-26 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
US9872949B2 (en) | 2013-02-01 | 2018-01-23 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
US9884145B2 (en) | 2013-11-26 | 2018-02-06 | Medtronic, Inc. | Parallel modules for in-line recharging of sorbents using alternate duty cycles |
US9895477B2 (en) | 2013-11-26 | 2018-02-20 | Medtronic, Inc. | Detachable module for recharging sorbent materials with optional bypass |
US9895479B2 (en) | 2014-12-10 | 2018-02-20 | Medtronic, Inc. | Water management system for use in dialysis |
US9943780B2 (en) | 2013-11-26 | 2018-04-17 | Medtronic, Inc. | Module for in-line recharging of sorbent materials with optional bypass |
US9943633B2 (en) | 2009-09-30 | 2018-04-17 | Medtronic Inc. | System and method to regulate ultrafiltration |
US10004839B2 (en) | 2013-11-26 | 2018-06-26 | Medtronic, Inc. | Multi-use sorbent cartridge |
US10010663B2 (en) | 2013-02-01 | 2018-07-03 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US10016553B2 (en) | 2014-06-24 | 2018-07-10 | Medtronic, Inc. | Replenishing urease in dialysis systems using a urease introducer |
US10076283B2 (en) | 2013-11-04 | 2018-09-18 | Medtronic, Inc. | Method and device to manage fluid volumes in the body |
US10098993B2 (en) | 2014-12-10 | 2018-10-16 | Medtronic, Inc. | Sensing and storage system for fluid balance |
US10124274B2 (en) | 2014-06-24 | 2018-11-13 | Medtronic, Inc. | Replenishing urease in dialysis systems using urease pouches |
US10172991B2 (en) | 2014-06-24 | 2019-01-08 | Medtronic, Inc. | Modular dialysate regeneration assembly |
US10272363B2 (en) | 2014-06-24 | 2019-04-30 | Medtronic, Inc. | Urease introduction system for replenishing urease in a sorbent cartridge |
US10286380B2 (en) | 2014-06-24 | 2019-05-14 | Medtronic, Inc. | Sorbent pouch |
US10343145B2 (en) | 2013-11-26 | 2019-07-09 | Medtronic, Inc. | Zirconium phosphate recharging method and apparatus |
US10357757B2 (en) | 2014-06-24 | 2019-07-23 | Medtronic, Inc. | Stacked sorbent assembly |
US10537875B2 (en) | 2013-11-26 | 2020-01-21 | Medtronic, Inc. | Precision recharging of sorbent materials using patient and session data |
US10543052B2 (en) | 2013-02-01 | 2020-01-28 | Medtronic, Inc. | Portable dialysis cabinet |
US10583236B2 (en) | 2013-01-09 | 2020-03-10 | Medtronic, Inc. | Recirculating dialysate fluid circuit for blood measurement |
US10595775B2 (en) | 2013-11-27 | 2020-03-24 | Medtronic, Inc. | Precision dialysis monitoring and synchronization system |
US10695481B2 (en) | 2011-08-02 | 2020-06-30 | Medtronic, Inc. | Hemodialysis system having a flow path with a controlled compliant volume |
US10850016B2 (en) | 2013-02-01 | 2020-12-01 | Medtronic, Inc. | Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection |
US10857277B2 (en) | 2011-08-16 | 2020-12-08 | Medtronic, Inc. | Modular hemodialysis system |
US10874787B2 (en) | 2014-12-10 | 2020-12-29 | Medtronic, Inc. | Degassing system for dialysis |
US10905816B2 (en) | 2012-12-10 | 2021-02-02 | Medtronic, Inc. | Sodium management system for hemodialysis |
US10960381B2 (en) | 2017-06-15 | 2021-03-30 | Medtronic, Inc. | Zirconium phosphate disinfection recharging and conditioning |
US10981148B2 (en) | 2016-11-29 | 2021-04-20 | Medtronic, Inc. | Zirconium oxide module conditioning |
US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
US11033667B2 (en) | 2018-02-02 | 2021-06-15 | Medtronic, Inc. | Sorbent manifold for a dialysis system |
US11110215B2 (en) | 2018-02-23 | 2021-09-07 | Medtronic, Inc. | Degasser and vent manifolds for dialysis |
US11154648B2 (en) | 2013-01-09 | 2021-10-26 | Medtronic, Inc. | Fluid circuits for sorbent cartridge with sensors |
US11167070B2 (en) | 2017-01-30 | 2021-11-09 | Medtronic, Inc. | Ganged modular recharging system |
US11213616B2 (en) | 2018-08-24 | 2022-01-04 | Medtronic, Inc. | Recharge solution for zirconium phosphate |
US11278654B2 (en) | 2017-12-07 | 2022-03-22 | Medtronic, Inc. | Pneumatic manifold for a dialysis system |
US11395868B2 (en) | 2015-11-06 | 2022-07-26 | Medtronic, Inc. | Dialysis prescription optimization for decreased arrhythmias |
US11565029B2 (en) | 2013-01-09 | 2023-01-31 | Medtronic, Inc. | Sorbent cartridge with electrodes |
US11806456B2 (en) | 2018-12-10 | 2023-11-07 | Mozarc Medical Us Llc | Precision peritoneal dialysis therapy based on dialysis adequacy measurements |
US11806457B2 (en) | 2018-11-16 | 2023-11-07 | Mozarc Medical Us Llc | Peritoneal dialysis adequacy meaurements |
US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
US11883576B2 (en) | 2016-08-10 | 2024-01-30 | Mozarc Medical Us Llc | Peritoneal dialysis intracycle osmotic agent adjustment |
US11944733B2 (en) | 2021-11-18 | 2024-04-02 | Mozarc Medical Us Llc | Sodium and bicarbonate control |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605214B1 (en) * | 1999-03-03 | 2003-08-12 | Prismedical Corporation | Devices for preparing hemodialysis solutions |
US6274103B1 (en) * | 1999-03-26 | 2001-08-14 | Prismedical Corporation | Apparatus and method for preparation of a peritoneal dialysis solution |
MXPA01008811A (en) * | 1999-03-03 | 2003-07-21 | Prismedical Corp | Improved water purification pack. |
DE19955578C1 (en) * | 1999-11-18 | 2001-09-06 | Fresenius Medical Care De Gmbh | Multi-chamber container, with glucose concentrate compartment and hydrochloric acid concentrate compartment |
US6627164B1 (en) * | 2000-11-28 | 2003-09-30 | Renal Solutions, Inc. | Sodium zirconium carbonate and zirconium basic carbonate and methods of making the same |
US7033498B2 (en) * | 2000-11-28 | 2006-04-25 | Renal Solutions, Inc. | Cartridges useful in cleaning dialysis solutions |
AU2002309676A1 (en) | 2001-05-04 | 2002-11-18 | Prismedical Corporation | Dual chamber dissolution container with passive agitation |
US7250619B2 (en) * | 2001-05-14 | 2007-07-31 | Prismedical Corporation | Powered sterile solution device |
JP4370552B2 (en) * | 2001-09-14 | 2009-11-25 | ニプロ株式会社 | Chemical solution injection port |
US6878283B2 (en) * | 2001-11-28 | 2005-04-12 | Renal Solutions, Inc. | Filter cartridge assemblies and methods for filtering fluids |
DE10162959B4 (en) * | 2001-12-20 | 2017-10-12 | Fresenius Medical Care Deutschland Gmbh | Container containing at least two solids and its use |
DE10162969A1 (en) * | 2001-12-20 | 2003-07-10 | Loegeljet S A M | Device and method for visualizing objects in an aerosol, such as mist, and uses thereof |
WO2003103533A2 (en) * | 2002-06-06 | 2003-12-18 | Nxstage Medical, Inc. | Last-chance quality check and/or air/pyrogen filter for infusion systems |
DE60336724D1 (en) | 2002-07-19 | 2011-05-26 | Baxter Healthcare Sa | SYSTEM FOR PERITONEAL DIALYSIS |
US6746514B2 (en) * | 2002-08-08 | 2004-06-08 | Baxter International Inc. | Gas venting device and a system and method for venting a gas from a liquid delivery system |
US9700663B2 (en) | 2005-01-07 | 2017-07-11 | Nxstage Medical, Inc. | Filtration system for preparation of fluids for medical applications |
ATE434454T1 (en) | 2003-01-07 | 2009-07-15 | Nxstage Medical Inc | BATCH FILTRATION SYSTEM FOR PRODUCING A STERILE REPLACEMENT LIQUID FOR KIDNEY TREATMENTS |
US20080210606A1 (en) | 2004-01-07 | 2008-09-04 | Jeffrey Burbank | Filtration System Preparation of Fluids for Medical Applications |
US7311829B2 (en) * | 2003-02-13 | 2007-12-25 | H2Q Water Industries, Ltd. | Water conversion device |
WO2004084973A2 (en) * | 2003-03-24 | 2004-10-07 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
WO2007041430A2 (en) * | 2005-10-03 | 2007-04-12 | Emv Technologies, Llc | Apparatus and method for enhanced hemodialysis performance |
US20080035568A1 (en) * | 2005-10-03 | 2008-02-14 | Zhongping Huang | Apparatus and Method for Filtering Fluids |
US8469331B2 (en) * | 2006-04-07 | 2013-06-25 | Nxstage Medical, Inc. | Filtration system for preparation of fluids for medical applications |
EA200900017A1 (en) * | 2006-06-14 | 2009-10-30 | Аква-Ну Фильтрейшн Системс Лимитед | FILTERING DEVICE FOR LIQUID FILTRATION FROM SOURCE |
US20080105618A1 (en) * | 2006-10-27 | 2008-05-08 | Mesosystems Technology, Inc. | Method and apparatus for the removal of harmful contaminants from portable drinking water devices |
EP2125160A1 (en) * | 2007-03-19 | 2009-12-02 | Pall Corporation | Fluid treatment elements and fluid treatment arrangements with fluid treatment elements having different fluid treatment characteristics and methods for making and using them |
US7736328B2 (en) | 2007-07-05 | 2010-06-15 | Baxter International Inc. | Dialysis system having supply container autoconnection |
US7892423B2 (en) * | 2008-02-14 | 2011-02-22 | Baxter International Inc. | Dialysis system including multi-heater power coordination |
US10973968B2 (en) | 2008-02-14 | 2021-04-13 | Baxter International Inc. | Control of a water device via a dialysis machine user interface |
US20090214807A1 (en) | 2008-02-27 | 2009-08-27 | Shawn Davis | Peelable seals including porous inserts |
US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
US10265454B2 (en) | 2008-07-25 | 2019-04-23 | Baxter International Inc. | Dialysis system with flow regulation device |
US20100051552A1 (en) * | 2008-08-28 | 2010-03-04 | Baxter International Inc. | In-line sensors for dialysis applications |
CA2803458C (en) | 2010-06-23 | 2018-02-13 | Gambro Lundia Ab | Dialysis precursor composition |
PL2585076T3 (en) | 2010-06-23 | 2015-08-31 | Gambro Lundia Ab | Dialysis precursor composition |
CN103037724A (en) * | 2010-06-29 | 2013-04-10 | 罗纳托·罗森塔尔 | Therapeutic brain cooling system and spinal cord cooling system |
US9045352B2 (en) | 2010-08-20 | 2015-06-02 | Stryker Corporation | Total fluid management system |
US9585810B2 (en) | 2010-10-14 | 2017-03-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
US20120199205A1 (en) | 2011-02-03 | 2012-08-09 | Fresenius Medical Care Deutschland Gmbh | System for preparing a medical fluid and method for preparing a medical fluid |
US20120219633A1 (en) * | 2011-02-28 | 2012-08-30 | Pall Corporation | Removal of immunoglobulins and leukocytes from biological fluids |
FR2975302B1 (en) | 2011-05-18 | 2013-05-10 | Fresenius Medical Care De Gmbh | CONNECTOR FOR DIALYSIS CONTAINER, CONTAINER HAVING SUCH CONNECTOR, METHOD FOR MANUFACTURING AND FILLING SUCH CONNECTORS AND CONTAINERS |
CN103747789B (en) | 2011-06-20 | 2016-04-20 | 甘布罗伦迪亚股份公司 | Dialysis precursor composition |
US9616161B2 (en) | 2011-06-20 | 2017-04-11 | Gambro Lundia Ab | Dialysis precursor composition |
MY171156A (en) | 2011-06-24 | 2019-09-27 | Richard W C Lo | Multi-container systems and uses thereof |
FR2978914B1 (en) * | 2011-08-11 | 2013-08-16 | Fresenius Medical Care De Gmbh | CONTAINER FOR DIALYSIS |
WO2013055283A1 (en) * | 2011-10-11 | 2013-04-18 | Soinial Ab | Bag and method for intravenous or intracorporeal administration of medical solution to a patient |
US20130146541A1 (en) | 2011-12-13 | 2013-06-13 | Nxstage Medical, Inc. | Fluid purification methods, devices, and systems |
ES2684218T3 (en) | 2011-12-21 | 2018-10-01 | Gambro Lundia Ab | Precursor Dialysis Composition |
ES2684193T3 (en) | 2011-12-21 | 2018-10-01 | Gambro Lundia Ab | Precursor Dialysis Composition |
SE536913C2 (en) | 2012-03-08 | 2014-10-28 | Gambro Lundia Ab | Composition for dialysis |
JP6138421B2 (en) * | 2012-04-16 | 2017-05-31 | アイティーアイ株式会社 | Dialysis treatment device monitoring system and dialysis treatment device monitoring method |
AU2013201546B2 (en) | 2012-12-18 | 2014-10-23 | Gambro Lundia Ab | Dialysis composition |
US9867918B2 (en) | 2014-03-17 | 2018-01-16 | Fresenius Medical Care Holdings, Inc. | Cartridges useful in cleaning dialysis solutions |
CA2985719C (en) | 2015-06-25 | 2024-03-26 | Gambro Lundia Ab | Medical device system and method having a distributed database |
WO2017048358A1 (en) | 2015-09-16 | 2017-03-23 | Fresenius Medical Care Holdings, Inc. | Cartridges useful in cleaning dialysis solutions |
JP7063468B2 (en) | 2015-09-21 | 2022-05-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Nutritional treatment for cancer |
DE102016107485A1 (en) * | 2016-04-22 | 2017-10-26 | Poromembrane Gmbh | Water treatment device |
US10545137B2 (en) | 2016-04-22 | 2020-01-28 | Becton, Dickinson And Company | Multiplex polymeric dye devices and methods for using the same |
US11045596B2 (en) | 2016-05-06 | 2021-06-29 | Gambro Lundia Ab | Systems and methods for peritoneal dialysis having point of use dialysis fluid preparation using water accumulator and disposable set |
WO2018114346A1 (en) | 2016-12-21 | 2018-06-28 | Gambro Lundia Ab | Medical device system including information technology infrastructure having secure cluster domain supporting external domain |
DE102017000533A1 (en) * | 2017-01-11 | 2018-07-12 | Fresenius Medical Care Deutschland Gmbh | Apparatus and method for the preparation of ready-to-use solutions for peritoneal dialysis |
US11320437B2 (en) | 2017-02-08 | 2022-05-03 | Becton, Dickinson And Company | Dried dye reagent devices and methods for making and using the same |
US10507165B2 (en) | 2017-05-31 | 2019-12-17 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using same |
US10369077B2 (en) | 2017-05-31 | 2019-08-06 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using the same |
CA3084319A1 (en) * | 2017-12-11 | 2019-06-20 | Filtricine, Inc. | Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy |
EP3880334A4 (en) * | 2018-11-13 | 2022-07-06 | Becton, Dickinson and Company | Dried reagent strainers and methods for making and using the same |
DE102020208801A1 (en) | 2020-07-15 | 2022-01-20 | Mahle International Gmbh | Ion exchanger for a fuel cell system |
Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3730349A (en) * | 1970-04-29 | 1973-05-01 | W Herrmann | Ion exchange filter particularly a miniature filter |
US4196081A (en) * | 1978-04-13 | 1980-04-01 | Pavia Edgar H | Apparatus for emergency water purification |
US4231872A (en) * | 1977-11-25 | 1980-11-04 | Wolfgang Keil | Device for complete desalination of water |
US4280912A (en) * | 1978-05-22 | 1981-07-28 | Darco Water Systems, Inc. | Water purification unit and method |
US4473474A (en) * | 1980-10-27 | 1984-09-25 | Amf Inc. | Charge modified microporous membrane, process for charge modifying said membrane and process for filtration of fluid |
US4495067A (en) * | 1980-12-02 | 1985-01-22 | Tracor, Inc. | Apparatus for preparation of infusion grade water |
US4523995A (en) * | 1981-10-19 | 1985-06-18 | Pall Corporation | Charge-modified microfiber filter sheets |
US4756838A (en) * | 1980-02-21 | 1988-07-12 | Veltman Preston Leonard | Preparation of dry dialysate products |
US4784772A (en) * | 1986-06-17 | 1988-11-15 | Mitsui Toatsu Chemicals, Incorporated | Method for the production and use of ultrapure water and apparatus therefor |
US4871463A (en) * | 1988-08-23 | 1989-10-03 | Sepratech | Vertical reaction vessel |
US4883596A (en) * | 1987-03-31 | 1989-11-28 | Tokyo Organic Chemical Industries, Ltd. | Carbonaceous adsorbent for removal of pyrogen and method of producing pure water using same |
US5071558A (en) * | 1989-08-11 | 1991-12-10 | Nikkiso Co., Ltd. | Sodium bicarbonate dialysate |
US5084558A (en) * | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
US5110479A (en) * | 1988-12-30 | 1992-05-05 | Frommer Moshe A | Water purification systems |
US5128035A (en) * | 1990-03-15 | 1992-07-07 | Clack Corporation | Fluid flow control device for water treatment systems |
US5211973A (en) * | 1986-01-24 | 1993-05-18 | Innova/Pure Water, Inc. | Water treatment apparatus |
US5259954A (en) * | 1991-12-16 | 1993-11-09 | Sepratech, Inc. | Portable intravenous solution preparation apparatus and method |
US5264555A (en) * | 1992-07-14 | 1993-11-23 | Enzon, Inc. | Process for hemoglobin extraction and purification |
US5395323A (en) * | 1989-10-26 | 1995-03-07 | Aktiebolaget Astra | Dissolution system |
US5494585A (en) * | 1992-03-02 | 1996-02-27 | Cox; Dale W. | Water remediation and purification system and method |
US5685980A (en) * | 1996-03-07 | 1997-11-11 | Patapoff; Walter | Miniaturized handheld desalination field unit |
US5779911A (en) * | 1996-04-10 | 1998-07-14 | Haug; Irving M. | Aqueous fluid purification monitoring and control system and process |
US5868924A (en) * | 1997-02-14 | 1999-02-09 | Barnstead/Thermolyne Corporation | Water purifier |
US5922378A (en) * | 1997-11-26 | 1999-07-13 | Kagan; Michael | Water filtration vessel |
US6110375A (en) * | 1994-01-11 | 2000-08-29 | Millipore Corporation | Process for purifying water |
US6274103B1 (en) * | 1999-03-26 | 2001-08-14 | Prismedical Corporation | Apparatus and method for preparation of a peritoneal dialysis solution |
US6605214B1 (en) * | 1999-03-03 | 2003-08-12 | Prismedical Corporation | Devices for preparing hemodialysis solutions |
US20060115395A1 (en) * | 1999-03-03 | 2006-06-01 | Taylor Michael A | Apparatus and method for preparation of a peritoneal dialysis solution |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4467588A (en) * | 1982-04-06 | 1984-08-28 | Baxter Travenol Laboratories, Inc. | Separated packaging and sterile processing for liquid-powder mixing |
US4548606A (en) * | 1983-09-29 | 1985-10-22 | Abbott Laboratories | Dual compartmented container with activating means |
US4784495A (en) * | 1987-02-06 | 1988-11-15 | Gambro Ab | System for preparing a fluid intended for a medical procedure by mixing at least one concentrate in powder form with water |
US5511875A (en) * | 1990-02-19 | 1996-04-30 | Gambro Ab | System for the preparation of a fluid concentrate intended for medical use |
SE467816B (en) * | 1990-02-19 | 1992-09-21 | Gambro Ab | SYSTEM FOR PREPARING A SCIENTIFIC INTENDED FOR MEDICAL USE |
-
1999
- 1999-03-26 US US09/277,448 patent/US6274103B1/en not_active Expired - Fee Related
- 1999-07-30 US US09/364,631 patent/US6719745B1/en not_active Expired - Fee Related
-
2001
- 2001-07-18 US US09/908,785 patent/US6426056B2/en not_active Expired - Fee Related
-
2002
- 2002-07-30 US US10/210,422 patent/US6623709B2/en not_active Expired - Fee Related
-
2003
- 2003-01-08 US US10/339,702 patent/US6814724B2/en not_active Expired - Fee Related
- 2003-09-16 US US10/664,215 patent/US6986872B2/en not_active Expired - Fee Related
-
2004
- 2004-11-09 US US10/997,096 patent/US20050113796A1/en not_active Abandoned
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3730349A (en) * | 1970-04-29 | 1973-05-01 | W Herrmann | Ion exchange filter particularly a miniature filter |
US4231872A (en) * | 1977-11-25 | 1980-11-04 | Wolfgang Keil | Device for complete desalination of water |
US4196081A (en) * | 1978-04-13 | 1980-04-01 | Pavia Edgar H | Apparatus for emergency water purification |
US4280912A (en) * | 1978-05-22 | 1981-07-28 | Darco Water Systems, Inc. | Water purification unit and method |
US4756838A (en) * | 1980-02-21 | 1988-07-12 | Veltman Preston Leonard | Preparation of dry dialysate products |
US4473474A (en) * | 1980-10-27 | 1984-09-25 | Amf Inc. | Charge modified microporous membrane, process for charge modifying said membrane and process for filtration of fluid |
US4495067A (en) * | 1980-12-02 | 1985-01-22 | Tracor, Inc. | Apparatus for preparation of infusion grade water |
US4523995A (en) * | 1981-10-19 | 1985-06-18 | Pall Corporation | Charge-modified microfiber filter sheets |
US5211973A (en) * | 1986-01-24 | 1993-05-18 | Innova/Pure Water, Inc. | Water treatment apparatus |
US4784772A (en) * | 1986-06-17 | 1988-11-15 | Mitsui Toatsu Chemicals, Incorporated | Method for the production and use of ultrapure water and apparatus therefor |
US4883596A (en) * | 1987-03-31 | 1989-11-28 | Tokyo Organic Chemical Industries, Ltd. | Carbonaceous adsorbent for removal of pyrogen and method of producing pure water using same |
US5084558A (en) * | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
US4871463A (en) * | 1988-08-23 | 1989-10-03 | Sepratech | Vertical reaction vessel |
US5110479A (en) * | 1988-12-30 | 1992-05-05 | Frommer Moshe A | Water purification systems |
US5071558A (en) * | 1989-08-11 | 1991-12-10 | Nikkiso Co., Ltd. | Sodium bicarbonate dialysate |
US5395323A (en) * | 1989-10-26 | 1995-03-07 | Aktiebolaget Astra | Dissolution system |
US5128035A (en) * | 1990-03-15 | 1992-07-07 | Clack Corporation | Fluid flow control device for water treatment systems |
US5725777A (en) * | 1991-12-16 | 1998-03-10 | Prismedical Corporation | Reagent/drug cartridge |
US5259954A (en) * | 1991-12-16 | 1993-11-09 | Sepratech, Inc. | Portable intravenous solution preparation apparatus and method |
US5494585A (en) * | 1992-03-02 | 1996-02-27 | Cox; Dale W. | Water remediation and purification system and method |
US5264555A (en) * | 1992-07-14 | 1993-11-23 | Enzon, Inc. | Process for hemoglobin extraction and purification |
US6110375A (en) * | 1994-01-11 | 2000-08-29 | Millipore Corporation | Process for purifying water |
US5685980A (en) * | 1996-03-07 | 1997-11-11 | Patapoff; Walter | Miniaturized handheld desalination field unit |
US5779911A (en) * | 1996-04-10 | 1998-07-14 | Haug; Irving M. | Aqueous fluid purification monitoring and control system and process |
US5868924A (en) * | 1997-02-14 | 1999-02-09 | Barnstead/Thermolyne Corporation | Water purifier |
US5922378A (en) * | 1997-11-26 | 1999-07-13 | Kagan; Michael | Water filtration vessel |
US6858139B2 (en) * | 1999-03-03 | 2005-02-22 | Prismedical Corporation | Methods and devices for preparing hemodialysis solutions |
US20060115395A1 (en) * | 1999-03-03 | 2006-06-01 | Taylor Michael A | Apparatus and method for preparation of a peritoneal dialysis solution |
US6605214B1 (en) * | 1999-03-03 | 2003-08-12 | Prismedical Corporation | Devices for preparing hemodialysis solutions |
US20050167363A1 (en) * | 1999-03-03 | 2005-08-04 | Taylor Michael A. | Methods and devices for preparing hemodialysis solutions |
US6274103B1 (en) * | 1999-03-26 | 2001-08-14 | Prismedical Corporation | Apparatus and method for preparation of a peritoneal dialysis solution |
US6814724B2 (en) * | 1999-03-26 | 2004-11-09 | Prismedical Corporation | Water purification pack |
US6719745B1 (en) * | 1999-03-26 | 2004-04-13 | Prismedical Corporation | Water purification pack |
US6623709B2 (en) * | 1999-03-26 | 2003-09-23 | Prismedical Corporation | Apparatus and method for preparation of a peritoneal dialysis solution |
US6986872B2 (en) * | 1999-03-26 | 2006-01-17 | Prismedical Corporation | Apparatus and method for preparation of a peritoneal dialysis solution |
US6426056B2 (en) * | 1999-03-26 | 2002-07-30 | Prismedical Corporation | Apparatus and method for preparation of a peritoneal dialysis solution |
Cited By (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9289165B2 (en) | 2005-02-07 | 2016-03-22 | Medtronic, Inc. | Ion imbalance detector |
US20060180550A1 (en) * | 2005-02-16 | 2006-08-17 | Metal & Arsenic Removal Technology | Portable water purifier |
US9943633B2 (en) | 2009-09-30 | 2018-04-17 | Medtronic Inc. | System and method to regulate ultrafiltration |
US20120012539A1 (en) * | 2010-01-08 | 2012-01-19 | Qiagen Gaithersburg Inc. | Water treatment apparatus and method for using same |
US9848778B2 (en) | 2011-04-29 | 2017-12-26 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
US10967112B2 (en) | 2011-04-29 | 2021-04-06 | Medtronic, Inc. | Adaptive system for blood fluid removal |
US11759557B2 (en) | 2011-04-29 | 2023-09-19 | Mozarc Medical Us Llc | Adaptive system for blood fluid removal |
US9597440B2 (en) | 2011-04-29 | 2017-03-21 | Medtronic, Inc. | Fluid volume monitoring for patients with renal disease |
US9642960B2 (en) | 2011-04-29 | 2017-05-09 | Medtronic, Inc. | Monitoring fluid volume for patients with renal disease |
US9700661B2 (en) | 2011-04-29 | 2017-07-11 | Medtronic, Inc. | Chronic pH or electrolyte monitoring |
US10506933B2 (en) | 2011-04-29 | 2019-12-17 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
US10207041B2 (en) | 2011-04-29 | 2019-02-19 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
US10293092B2 (en) | 2011-04-29 | 2019-05-21 | Medtronic, Inc. | Electrolyte and pH monitoring for fluid removal processes |
US10835656B2 (en) | 2011-04-29 | 2020-11-17 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
US9750862B2 (en) | 2011-04-29 | 2017-09-05 | Medtronic, Inc. | Adaptive system for blood fluid removal |
US10406268B2 (en) | 2011-04-29 | 2019-09-10 | Medtronic, Inc. | Blood fluid removal system performance monitoring |
US10179198B2 (en) | 2011-04-29 | 2019-01-15 | Medtronic, Inc. | Electrolyte and pH monitoring for fluid removal processes |
US9192707B2 (en) | 2011-04-29 | 2015-11-24 | Medtronic, Inc. | Electrolyte and pH monitoring for fluid removal processes |
US9968721B2 (en) | 2011-04-29 | 2018-05-15 | Medtronic, Inc. | Monitoring fluid volume for patients with renal disease |
US9456755B2 (en) | 2011-04-29 | 2016-10-04 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
US10064985B2 (en) | 2011-04-29 | 2018-09-04 | Medtronic, Inc. | Precision blood fluid removal therapy based on patient monitoring |
US10695481B2 (en) | 2011-08-02 | 2020-06-30 | Medtronic, Inc. | Hemodialysis system having a flow path with a controlled compliant volume |
US10722636B2 (en) | 2011-08-02 | 2020-07-28 | Medtronic, Inc. | Hemodialysis system having a flow path with a controlled compliant volume |
US10857277B2 (en) | 2011-08-16 | 2020-12-08 | Medtronic, Inc. | Modular hemodialysis system |
US9707330B2 (en) | 2011-08-22 | 2017-07-18 | Medtronic, Inc. | Dual flow sorbent cartridge |
US9713668B2 (en) | 2012-01-04 | 2017-07-25 | Medtronic, Inc. | Multi-staged filtration system for blood fluid removal |
US10905816B2 (en) | 2012-12-10 | 2021-02-02 | Medtronic, Inc. | Sodium management system for hemodialysis |
US10881777B2 (en) | 2013-01-09 | 2021-01-05 | Medtronic, Inc. | Recirculating dialysate fluid circuit for blood measurement |
US11857712B2 (en) | 2013-01-09 | 2024-01-02 | Mozarc Medical Us Llc | Recirculating dialysate fluid circuit for measurement of blood solute species |
US10583236B2 (en) | 2013-01-09 | 2020-03-10 | Medtronic, Inc. | Recirculating dialysate fluid circuit for blood measurement |
US11154648B2 (en) | 2013-01-09 | 2021-10-26 | Medtronic, Inc. | Fluid circuits for sorbent cartridge with sensors |
US11565029B2 (en) | 2013-01-09 | 2023-01-31 | Medtronic, Inc. | Sorbent cartridge with electrodes |
US9707328B2 (en) | 2013-01-09 | 2017-07-18 | Medtronic, Inc. | Sorbent cartridge to measure solute concentrations |
US10543052B2 (en) | 2013-02-01 | 2020-01-28 | Medtronic, Inc. | Portable dialysis cabinet |
US10850016B2 (en) | 2013-02-01 | 2020-12-01 | Medtronic, Inc. | Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection |
US11786645B2 (en) | 2013-02-01 | 2023-10-17 | Mozarc Medical Us Llc | Fluid circuit for delivery of renal replacement therapies |
US9526822B2 (en) | 2013-02-01 | 2016-12-27 | Medtronic, Inc. | Sodium and buffer source cartridges for use in a modular controlled compliant flow path |
US9872949B2 (en) | 2013-02-01 | 2018-01-23 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
US10010663B2 (en) | 2013-02-01 | 2018-07-03 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US10561776B2 (en) | 2013-02-01 | 2020-02-18 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US10532141B2 (en) | 2013-02-01 | 2020-01-14 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
US9144640B2 (en) | 2013-02-02 | 2015-09-29 | Medtronic, Inc. | Sorbent cartridge configurations for improved dialysate regeneration |
US9855379B2 (en) | 2013-02-02 | 2018-01-02 | Medtronic, Inc. | Sorbent cartridge configurations for improved dialysate regeneration |
US9827361B2 (en) | 2013-02-02 | 2017-11-28 | Medtronic, Inc. | pH buffer measurement system for hemodialysis systems |
US10076283B2 (en) | 2013-11-04 | 2018-09-18 | Medtronic, Inc. | Method and device to manage fluid volumes in the body |
US11064894B2 (en) | 2013-11-04 | 2021-07-20 | Medtronic, Inc. | Method and device to manage fluid volumes in the body |
US10071323B2 (en) | 2013-11-26 | 2018-09-11 | Medtronic, Inc | Module for in-line recharging of sorbent materials with optional bypass |
US10478545B2 (en) | 2013-11-26 | 2019-11-19 | Medtronic, Inc. | Parallel modules for in-line recharging of sorbents using alternate duty cycles |
US10537875B2 (en) | 2013-11-26 | 2020-01-21 | Medtronic, Inc. | Precision recharging of sorbent materials using patient and session data |
US10343145B2 (en) | 2013-11-26 | 2019-07-09 | Medtronic, Inc. | Zirconium phosphate recharging method and apparatus |
US11219880B2 (en) | 2013-11-26 | 2022-01-11 | Medtronic, Inc | System for precision recharging of sorbent materials using patient and session data |
US10004839B2 (en) | 2013-11-26 | 2018-06-26 | Medtronic, Inc. | Multi-use sorbent cartridge |
US9943780B2 (en) | 2013-11-26 | 2018-04-17 | Medtronic, Inc. | Module for in-line recharging of sorbent materials with optional bypass |
US9884145B2 (en) | 2013-11-26 | 2018-02-06 | Medtronic, Inc. | Parallel modules for in-line recharging of sorbents using alternate duty cycles |
US9895477B2 (en) | 2013-11-26 | 2018-02-20 | Medtronic, Inc. | Detachable module for recharging sorbent materials with optional bypass |
US11471100B2 (en) | 2013-11-27 | 2022-10-18 | Medtronic, Inc. | Precision dialysis monitoring and synchonization system |
US10595775B2 (en) | 2013-11-27 | 2020-03-24 | Medtronic, Inc. | Precision dialysis monitoring and synchronization system |
US10617349B2 (en) | 2013-11-27 | 2020-04-14 | Medtronic, Inc. | Precision dialysis monitoring and synchronization system |
US11471099B2 (en) | 2013-11-27 | 2022-10-18 | Medtronic, Inc. | Precision dialysis monitoring and synchronization system |
US10888800B2 (en) | 2014-06-24 | 2021-01-12 | Medtronic, Inc | Replenishing urease in dialysis systems using urease pouches |
US11045790B2 (en) | 2014-06-24 | 2021-06-29 | Medtronic, Inc. | Stacked sorbent assembly |
US10124274B2 (en) | 2014-06-24 | 2018-11-13 | Medtronic, Inc. | Replenishing urease in dialysis systems using urease pouches |
US10821214B2 (en) | 2014-06-24 | 2020-11-03 | Medtronic, Inc. | Urease introduction system for replenishing urease in a sorbent cartridge |
US10172991B2 (en) | 2014-06-24 | 2019-01-08 | Medtronic, Inc. | Modular dialysate regeneration assembly |
US10807068B2 (en) | 2014-06-24 | 2020-10-20 | Medtronic, Inc. | Sorbent pouch |
US10926017B2 (en) | 2014-06-24 | 2021-02-23 | Medtronic, Inc. | Modular dialysate regeneration assembly |
US10245365B2 (en) | 2014-06-24 | 2019-04-02 | Medtronic, Inc. | Replenisihing urease in dialysis systems using a urease introducer |
US10016553B2 (en) | 2014-06-24 | 2018-07-10 | Medtronic, Inc. | Replenishing urease in dialysis systems using a urease introducer |
US11673118B2 (en) | 2014-06-24 | 2023-06-13 | Mozarc Medical Us Llc | Stacked sorbent assembly |
US10272363B2 (en) | 2014-06-24 | 2019-04-30 | Medtronic, Inc. | Urease introduction system for replenishing urease in a sorbent cartridge |
US10286380B2 (en) | 2014-06-24 | 2019-05-14 | Medtronic, Inc. | Sorbent pouch |
US10357757B2 (en) | 2014-06-24 | 2019-07-23 | Medtronic, Inc. | Stacked sorbent assembly |
US10098993B2 (en) | 2014-12-10 | 2018-10-16 | Medtronic, Inc. | Sensing and storage system for fluid balance |
US9713665B2 (en) | 2014-12-10 | 2017-07-25 | Medtronic, Inc. | Degassing system for dialysis |
US10195327B2 (en) | 2014-12-10 | 2019-02-05 | Medtronic, Inc. | Sensing and storage system for fluid balance |
US10874787B2 (en) | 2014-12-10 | 2020-12-29 | Medtronic, Inc. | Degassing system for dialysis |
US10420872B2 (en) | 2014-12-10 | 2019-09-24 | Medtronic, Inc. | Degassing system for dialysis |
US9895479B2 (en) | 2014-12-10 | 2018-02-20 | Medtronic, Inc. | Water management system for use in dialysis |
US11395868B2 (en) | 2015-11-06 | 2022-07-26 | Medtronic, Inc. | Dialysis prescription optimization for decreased arrhythmias |
US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
US11883576B2 (en) | 2016-08-10 | 2024-01-30 | Mozarc Medical Us Llc | Peritoneal dialysis intracycle osmotic agent adjustment |
US11679186B2 (en) | 2016-09-09 | 2023-06-20 | Mozarc Medical Us Llc | Peritoneal dialysis fluid testing system |
US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
US11642654B2 (en) | 2016-11-29 | 2023-05-09 | Medtronic, Inc | Zirconium oxide module conditioning |
US10981148B2 (en) | 2016-11-29 | 2021-04-20 | Medtronic, Inc. | Zirconium oxide module conditioning |
US11167070B2 (en) | 2017-01-30 | 2021-11-09 | Medtronic, Inc. | Ganged modular recharging system |
US11883794B2 (en) | 2017-06-15 | 2024-01-30 | Mozarc Medical Us Llc | Zirconium phosphate disinfection recharging and conditioning |
US10960381B2 (en) | 2017-06-15 | 2021-03-30 | Medtronic, Inc. | Zirconium phosphate disinfection recharging and conditioning |
US11278654B2 (en) | 2017-12-07 | 2022-03-22 | Medtronic, Inc. | Pneumatic manifold for a dialysis system |
US11033667B2 (en) | 2018-02-02 | 2021-06-15 | Medtronic, Inc. | Sorbent manifold for a dialysis system |
US11110215B2 (en) | 2018-02-23 | 2021-09-07 | Medtronic, Inc. | Degasser and vent manifolds for dialysis |
US11213616B2 (en) | 2018-08-24 | 2022-01-04 | Medtronic, Inc. | Recharge solution for zirconium phosphate |
US11806457B2 (en) | 2018-11-16 | 2023-11-07 | Mozarc Medical Us Llc | Peritoneal dialysis adequacy meaurements |
US11806456B2 (en) | 2018-12-10 | 2023-11-07 | Mozarc Medical Us Llc | Precision peritoneal dialysis therapy based on dialysis adequacy measurements |
US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
US11944733B2 (en) | 2021-11-18 | 2024-04-02 | Mozarc Medical Us Llc | Sodium and bicarbonate control |
Also Published As
Publication number | Publication date |
---|---|
US6274103B1 (en) | 2001-08-14 |
US6623709B2 (en) | 2003-09-23 |
US20040057885A1 (en) | 2004-03-25 |
US6719745B1 (en) | 2004-04-13 |
US6986872B2 (en) | 2006-01-17 |
US20030012714A1 (en) | 2003-01-16 |
US6814724B2 (en) | 2004-11-09 |
US20010048909A1 (en) | 2001-12-06 |
US6426056B2 (en) | 2002-07-30 |
US20030105435A1 (en) | 2003-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6814724B2 (en) | Water purification pack | |
EP1177025A2 (en) | Improved water purification pack | |
US7300636B2 (en) | Method for producing a dialysate solution | |
AU2002217930B2 (en) | Cartridges useful in cleaning dialysis solutions | |
US7033498B2 (en) | Cartridges useful in cleaning dialysis solutions | |
JP2002538945A5 (en) | ||
US5725777A (en) | Reagent/drug cartridge | |
EP2228083B1 (en) | A device for removing uremic toxins in a dialysis procedure | |
US7250619B2 (en) | Powered sterile solution device | |
EP2804640B1 (en) | Method and composition for removing uremic toxins in dialysis processes | |
CN105120913A (en) | Sodium and buffer source cartridges for use in a modular controlled complaint flow path | |
CN105025951A (en) | Systems and methods for multifunctional volumeteric fluid control | |
CN105007958A (en) | Degassing module for a controlled compliant flow path | |
AU2002217930A1 (en) | Cartridges useful in cleaning dialysis solutions | |
US4313831A (en) | Process and device for the removal of waste metabolites from a solution containing such metabolites | |
CA2362774C (en) | Improved water purification pack | |
JP2002263639A (en) | Water purifier | |
Duncan | The production of USPXX water for injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PRISMEDICAL CORPORATION, CALIFORNIA Free format text: TERMINATION OF SECURITY AGREEMENT ('TERMINATION, WAIVER AND AMENDMENT AGREEMENT);ASSIGNORS:CRUTTENDEN, WALTER III;ISS MANAGEMENT D, LLC;REEL/FRAME:017286/0987 Effective date: 20020628 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: GF PRIVATE EQUITY GROUP, LLC, COLORADO Free format text: SECURITY AGREEMENT;ASSIGNOR:PRISMEDICAL CORPORATION;REEL/FRAME:022727/0486 Effective date: 20081015 |